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Abstract In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug 
delivery systems are based on the difference between cancer and healthy cells. Currently, 
nanotechnology-based delivery systems are the most pr mising tool to deliver DNA-based products to 
cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier 
for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA 
development and its mechanism of action. Overall, this review gives us a clear picture of lipid and 
polymer-based drug delivery systems, which in the future could form the base to translate the basic 
siRNA biology into siRNA-based cancer therapies.  
KEY WORDS Small interfering RNA (siRNA); Nanomedicine; Liposomes; Micelles; Cancer; Polymer 
1. Introduction  
In the recent past, one of the most transformed fields of science is molecular biology. This 










regulates gene expression. Based on their biological roles and structures, small non-coding RNAs are 
classified into three main categories: miRNAs, siRNAs, and piRNAs1.  
siRNA, also known as short interfering RNA, is a type of non-coding double-stranded RNA of 20‒ 3 
nucleotide base pairs in length. As the name suggests, it acts by interfering with the expression of the 
specific gene having a complementary sequence. The siRNA is similar to microRNA in terms of 
functions, except that the microRNA can regulate th expression of hundreds of genes via imperfect 
base pairing. In contrast, siRNA binds more specifically to the single gene at a particular location1. 
Although siRNA and miRNA are noncoding RNAs that share a common role in gene silencing and 
regulation, their mode of action and clinical potential are different. One of the significant differences 
between these two is that the miRNA has multiple targets, whereas siRNA has only one mRNA target. 
The clinical application of these two is thus, different from each other. The therapeutic potential of 
siRNAs and miRNAs is verified in the treatment of can er and certain other diseases and infections2.  
SiRNA is produced from the long dsRNAs and small hairpin RNAs with the help of enzyme dicer. It 
prevents the process of translation by degrading mRNA. This function of the siRNA is seen as one of 
the most critical therapeutic tools for the treatment of various genetic disorders, including cancer.  
2. SiRNA production and interference mechanism 
Sense and antisense strands of siRNA are transcribed from the same loci of the DNA template. This is 
the endogenous source of the small RNA molecules1. RNA molecules can also be introduced 
exogenously, which has already become a vital tool in laboratory medicine and research. Due to 
transcription from the same loci of DNA, RNA strands have the complementary sequence, which leads 
to the formation of the double-strand RNA molecules. Once formed, double-strand RNA, along with the 
associated proteins, moves in the cytosol through the nuclear pores where it cleaved to create the single 
strand siRNA. The enzyme responsible for the cleavage is the dicer, an RNase III type enzyme (RNA 
specific endonuclease). This cleavage leads to the overhang of two nucleotides at the 3′ ends and 
monophosphate at 5′ ends. siRNA thus formed, in association withith ARGONAUTE and other proteins,  
create  the silencing effector complex, which binds to the target mRNA via Watson–Crick base pairing. 
In most cases, silencing is the direct effect of this interaction. In short, after cleavage by dicer, the small 
RNA molecules of around 21 nucleotides are loaded on to the multiprotein complex (ribonucleoprotein), 
called RISC3. The loading efficiency of different siRNAs into the RISC varies considerably. Several 









Due to the variation of the loading efficacy, potency of the downstream effect of siRNA on gene 
silencing also varies. α-form helix is supposed to have the perfect and stable fit than the β-form helix to 
trigger the RNA interference4. In the case of the exogenous pathway (externally introduced siRNA), 
siRNA of the same length could directly load into the RISC without prior processing by the dicer 
enzyme4. Once loaded, one of the two strands (having the same nucleotide sequence with that of 
mRNA) separates from the RISC complex and degrades. This strand, which degrades, is called a 
passenger strand, and the strand having the complementary sequence to that of target mRNA is known 
as guide RNA. The guide strand remains attached to the RISC and guides the complex to the target 
mRNA. After proper recognition of the mRNA nucleotide sequence, complementary to that of guide 
RNA, the cleavage process starts4. The silencing of the target gene takes place by cleaving the mRNA 
around 10 to 11 nucleotides upstream of 5′ monophosphate end of the guide RNA. This process is 
catalysed with the help of enzyme Ago2, which is one f the most important components of RISCs. 
RISCs once cleave the target mRNA, undergoes recyclisation to carry out a similar event (Error! 
Reference source not found.)4. This model of target mRNA cleavage is supported by the in-vitro 
studies carried out by the Nykanen et al.5. They confirmed the formation of siRNA from dsRNA is ATP-
dependent, loading of siRNA to the RISC is ATP-independent, unwinding of the siRNA complex to 
generate reactant complex is ATP-dependent and identification and cleavage of the target site of the 
mRNA are ATP-independent process. The group also confirmed the cleavage of the target mRNA at a 
single site precisely in the region complementary to the nucleotide sequence of guide siRNA5. Further, 
the Hutvagner  et al.6 established that the RISC is recycled to be used multiple times, confirming its 
catalytic nature. 
 
3. SiRNA for cancer treatment  
Current research in oncology is focused on understanding and targeting the genetic changes in the 
cancer cells. Recent knowledge of the genetic mutations in the cancer cells has allowed us to use 
classical chemotherapeutic agents in a better way. This knowledge is also helping us to develop 
advanced non-classical gene-based therapeutic agents7. Among the non-classical, siRNA is a useful 
therapeutic tool to knock-down the genes which are di ctly or indirectly responsible for the abnormal 
proliferation of cancerous cells. This possibility has fueled optimism in gene-based cancer therapy. In 










front runner among the therapeutic interventions. The incredible gene silencing ability of siRNA has 
proven to be the crucial tool in understanding the genetic functions in plants and animals. Elbashir et al.8 
first demonstrated the gene silencing ability of 21- and 22-nucleotide siRNA produced by the enzymatic 
action of ribonuclease III on dsRNA. They confirmed the inhibition of genes in various mammalian cell 
lines, including HeLa and human HEK. Following this demonstration, it was realized that this function 
of siRNA could be developed into a non-conventional ew drug class that could directly inhibit the 
disease-causing or promoting genes. siRNA-based gene silencing is crucial for the targets which are not 
druggable or accessible to the small molecules, antibodies, or proteins9. Several in-vivo and in-vitro 
studies have confirmed that the abnormal cancerous cell proliferation could be significantly inhibited by 
siRNA-mediated silencing10. Moreover, siRNA has shown great promise in potentiati g chemotherapy 
by sensitizing the drug-resistant cancer cells11,12. Present comprehensive research is also focused on the 
identification of the genes that, when silenced, boost the sensitivity towards chemotherapy. Therapeutic 
agents developed to target these mutated genes not only have the potential to target the cancerous cell  
but, rescue the healthy cells from the collateral damage13. In the present scenario, RNA interference is a 
widely used tool to identify and target them. Numerous studies reporting the use of siRNA on increasing 
the sensitivity towards chemotherapy via silencing are available; the detail is summarized in Error! 
Reference source not found.14–42.  
Several genetic mutations in tumor suppressor and oncogene lead to the transformation of a normal 
to the cancerous cells. Numerous classical drugs tar et the critical signaling molecules and inhibit the 
proteins and enzymes which directly or indirectly alter the gene functions. In-depth knowledge of the 
loss of functions and gain of functions may help to use conventional medicines or investigate the new 
ones for better therapeutic outcomes. Loss of functio s and gain of functions of onco- or tumor-
suppressor genes could affect tumor growth, apoptosis, sensitivity to the chemo and radiotherapy, and 
development of resistance towards chemotherapy. Identification of the gene which enhances or inhibits 
the sensitivity towards the radiation or chemotherapy could be the attractive target for cancer treatmnt. 
Drugs identified to selectively target such genes have the potential to enhance the cytotoxic effect of 
therapy.  
Nowadays, gene silencing by siRNA is a crucial tool to pinpoint the gene responsible for the 
specific pathological condition. With extensive siRNA libraries available, it's easy to identify the targets 










the particular set of genes in tumorigenesis43. Presently, the RNA interference tools like siRNA are 
widely used in studying the mammalian cellular signalli g pathways. An in-depth exploration of cellular 
cell signalling pathways, especially in cancer cells, could help in the identification of the responsible 
genes. One very crucial example is the identification of the AKTcooperating kinases to enhance the 
action of Akt inhibitor. Morgan-Lappe et al.44 identified AKT cooperating kinases by screening a library 
of kinase-specific siRNA to enhance the cytotoxic effect of AKT inhibitor A-443654. There are a few 
other crucial signalling molecules responsible for cancer identified using RNAi, such as 1) Aza-Blanc et 
al. 45 identified modulators of TRAIL-induced apoptosis. 2) MacKeigan et al.46 identified phosphatases 
and kinases enzymes responsible for apoptosis and chemoresistance. 3) Futami et al.47 identified 
molecules involved in Thapsigargin-induced apoptosis.4) Brummelkamp et al.48 confirmed that the loss 
of cylindromatosis activates NF-κB and inhibits apoptosis. 5) Berns et al.49 in a large scale screening 
study carried out on human cells, identified several new components of the P53 cell signalling pathways. 
6) Kittler et al.50 identified several genes in HeLa cells, which are essential for cell division.  
Several in-vitro, animal, preclinical, and some clinical trials have confirmed the sequence-specific 
binding of siRNA to the mRNA, and its site-specific cleavage results in the downregulation or inhibition 
of the genes responsible for cancer or other pathological conditions51. Irrespective of site-specificity, 
recent clinical trials have identified several hurdles in its clinical translation, which include degradation 
by the ribonucleases enzymes, stability of siRNA molecules in physiological conditions, inflammation 
reactions, site-specific and controlled release of siRNA, and efficient delivery vehicle. All these barriers 
must be overcome for the success of the siRNA in cancer treatment. Chemical modification may be 
required to improve the stability and reduce the immune activation of siRNA molecules52. The carrier 
system, which could not only deliver the siRNA molecul s to the site of action but also protect it from 
the ribonucleases, is needed. PEGylated or tumour-targeting ligand conjugated nanoparticles composed 
of the lipids and other stimuli-sensitive polymers might improve the specificity and effectiveness of 
siRNA53. Although the siRNA has open new doors for the cancer treatment, it required fine-tuning to 
impart stability and delivery vehicle to carry it safely at the site of action. In the following section of the 
review, we have discussed the significant hurdles in siRNA delivery and the approaches which are under 










4. Recent advances in siRNA delivery to cancer cells 
Highly charged molecules like RNA have several unfavor ble characteristics, like rapid nucleases base 
destruction, enhanced clearance by the kidney, immune activation, and inefficient delivery to the cancer 
cells, which hindered its development. One major problem is its physiochemical characters; they are 
hydrophilic, negatively charged, and have a high molecular weight, which makes it impossible to cross 
the lipid membrane of the cell. Moreover, if siRNA enters via endocytosis, they could be subjected to a 
rapid degradation process during endosome lysosome trafficking and could not pass through the nuclear 
membrane54. The therapeutic success of siRNAs in cancer not oly depends on its delivery to the tumor 
site, but for the highest clinical benefit, it must be administered systemically or orally. For systemic 
delivery of the siRNA, the foremost hurdle clinical scientists facing are: 1) getting siRNA delivered to 
the specific gene site without affecting the healthy cells, 2) maintaining the optimum level of siRNA at 
the site of action, 3) enhancing its efficiency by increasing cellular uptake, and 4) monitor efficieni s. 
One of the approaches to overcome these challenges is the development of novel delivery systems. The 
ideal delivery system for the siRNA to the cancer clls should: 1) prevent the nuclease-based 
degradation, 2) promote targeted site delivery, 3) facilitate cellular internalization, 4) avoid endosomal 
pathway, and 5) release siRNA at the site of action54. 
Several siRNA delivery platforms are under clinical investigation. Non-viral systems include lipid-
based vectors (e.g., liposomes, PEGylated liposomes, lipidoids, etc.), organic and inorganic nano-
vectors, nanogels, peptide carriers (e.g., cell-penetrating peptides), etc. Non-viral delivry systems could 
deliver the siRNA with lesser safety concerns. They are easy to prepare, highly stable, non-mutagenic 
with excellent transfection efficiencies.  
4.1. Lipid-based vectors to transport siRNA  
Since the 1960s, liposomes underwent several changes that range from unilamellar vesicles composed of 
amphiphilic molecules to targeted liposomes for site- pecific drug delivery55. Liposomes can entrap 
hydrophilic molecules in their aqueous core, whereas the hydrophobic molecules get trapped inside the 
lipid layer. One essential advancement is its upgrade to the stealth liposomes. Stealth liposomes contain 
lipids complexed with polymers, mostly PEG, in such a way that polymers are directed outwards from 
the liposomes. Such modification prevents the identifica ion of the liposomes by the immune system and









present at the distal terminal of polymers, which help them to link with the targeting ligands (proteins, 
like peptides or antibodies). Functionalization at the distal terminal end could also help to introduce pH-
sensitive or hydrolysable groups to develop the pH- or chemical-sensitive liposomes. Cationic liposomes 
are one of the promising variations of the liposomes composed/of the cationic lipids and zwitterionic 
lipids, also called as the helper lipids. When such positively charged liposomes encounter the DNA 
molecule, they form the complex called lipoplex due to the electrostatic attraction between positively 
charged liposomes and negatively charged DNA molecules. Such complex on binding with the cell 
surface undergoes fusion and introduces DNA molecules inside the cells56. 
Felgner et al. 57 were the first who used the cationic lipids to transfect the cells with DNA. They 
used synthetic cationic lipid DOTMA for the preparation of liposomes. DOTMA facilitated the fusion of 
the liposomes with the lipid membrane of the cells. Fusion with the cell membrane has helped to achieve 
a high rate of DNA transfection57. During the last 30 years, different cationic lipids were developed to 
deliver the DNA and its products to the cells. Liposomes were the first delivery system developed from 
the cationic lipids. Most of the lipoplexes are nots lely made up of the cationic lipids but are compsed 
of the combination of lipids, such as DOPC or DOPE, CHOL, and some other natural lipids58–60. 
Liposomes composed of the combination of helper lipids like DOPC, DOPE, and DSPC, are found 
to have a better fusion character than the liposome ade up of only the cationic lipids61. Overall, the 
loading of siRNA into the liposomes occurs because of the electrostatic charges; and sometimes, 
chances of nonspecific interactions with the serum or plasma proteins increased. Such non-specific 
interactions could lead to the activation of the immunogenic response and rapid clearance from the 
circulation system62.  
4.1. 1. Advanced cationic lipid-based siRNA delivery system 
Cholesterol or DOPE is added to the cationic formulation not only to enhance the stability of the 
liposomes but also to enhance its cellular uptake63. Helper cationic polymers were introduced in the 
formulation to increase the siRNA entrapment inside th  liposome core. For example, protamine was 
added in the formulation (DOTAP/Chol) to increased siRNA entrapment64. To improve the siRNA 
loading capacity, cationic liposomes were formulated using AtuFECT01, neutral/helper lipid 
phospholipidDPhyPE, and DSPE-PEG65. The loading capacity of siRNA is also found to increase when 
it is modified chemically to conjugated to 2′-O-methyl, and 2′-fluoro and CHOL9. SiRNA modified with 










Other notable modified siRNAs are GalNAc-conjugated siRNA, 2-OMe-phosphorodithioate-modified 
siRNA (higher loading capacity in RISC), CHOL-conjugated siRNAs (having better pharmacokinetic 
characters), hydroxyethylglycine PNA (hegPNA)-capped 3′ and 5′ siRNAs (protection against serum 
nucleases) and hydrophobically-modified siRNAs (improved stability and higher internalisation)66,67.  
To improve the blood stability and pharmacokinetic characters, PEG was added to the cationic 
liposome formulation, which enhanced the blood circulation time68. A higher ratio of PEG enhances the 
circulation times but, at the same time, hampers the cellular uptake and endosomal escape, which means 
that the optimum ratio of the PEGylated lipids is es ential69. Wrapsomes were proposed by Yagi et al.70 
where siRNA/DOTAP forms the core, and neutral lipid b layer composed of egg phosphatidylcholine 
and PEG lipid forms the wrap. Wrapsomes were found to have improved circulation time along with 
higher stability70.  
The drawback of PEGylation, i.e., decreasing cellular uptake and endosomal escape, could be 
overcame by the approach of Carmona et al.71 The group coupled PEG-2000 dialdehyde to the cationic 
liposome composed of cholesteryl polyamine–N1-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine, 
neutral lipids (DOPE) and CHOL–PEG350 aminoxy lipid v a oxime linkage. This linkage is stable at pH 
7 but decomposes at pH 5, releasing the PEG but, at he same time, offers the advantage of 
PEGylation71. Such cationic liposomes linked with PEG via an oxime bridge could become an important 
delivery system for siRNA delivery in the acidic microenvironment of a tumor. Nanoparticles having 
PEG linked with lipids susceptible to the proteins l ke matrix metalloproteinasewas also developed72. 
Some biogenic materials like hyaluronic acid were also dded in the cationic liposome formulation 
to reduce immune identification. Such nanoparticles were found to enhance the siRNA delivery-
mediated silencing of luciferase in B16F10 tumor cells73. To take advantage of lipid-polymer-based 
nanoparticles, cationic lipid‒polymer hybrid nanoparticles were prepared by a single-step 
nanoprecipitation of a cationic lipid (N,N-bis(2-hydroxyethyl)-N-methyl-N-(2-cholesteryloxycarbonyl 
aminoethyl) ammonium bromide, BHEM-Chol) and amphiphil c polymers for systemic delivery of 
siRNA. The lipid polymeric nanoparticles were found to efficiently deliver the siRNA to BT474 cells 
and, at the same time, escape the loaded siRNA from the endosome into the cytoplasm74. 
To induce and enhance the cellular uptake and releas  of siRNA (endosomal escape), helper lipids 
like DOPE and 1,2-distear-oyl-sn-glycero-3-phosphocholine were added to the formulation of the 










and dioleoylphosphatidylethanolamine (DOPE)-based lipop exes were found to enhance the transfection 
efficiency of the siRNA 75. 
4.1.1.1.SNALP® 
One of the critical developments in the cationic siRNA delivery system is the introduction of SNALP76. 
In general, SNALPs consist of modified siRNA, which s enclosed inside the bilayer membrane made up 
of cationic‒zwitterionic lipids with an outermost shield of PEG. It is primarily made up of three distinct 
lipids: a cationic ionisable lipid (1,2-dilinoleyloxy-3-dimethylaminopropane), a helper lipid (Chol or 
fusogenic lipids), and a PEG lipid. The electrostatic force of attraction between the positive charge of 
the SNALP membrane and the negative charge of the cell membrane assists the process of cellular 
uptake76. 
In a study reported by Morrissey et al. 76, two siRNA, namely HBV263 and HBV1583, targeted to 
the hepatitis B virus were chemically modified to protect it from nucleases. The efficiency of these 
modified siRNAs was studied in the mouse model of hepatitis B virus by delivering it using SNALP 
system. Better efficacy of modified siRNA delivery via SNALP was observed when compared to the 
same but unmodified siRNA. At the same time, improved half-life in plasma was also noted. In 2006, 
Zimmermann et al. 77 have reported the first study of gene silencing in non-human primates. They 
described the silencing of the APOB gene, which is a target for heart disorders. APOB-specific siRNA 
entrapped inside the SNALP was administered via IV injection to the cynomolgus monkeys. SiRNA was 
found to cleave the mRNA at the site reported in the RNAi mechanism. Within the first 24 h, a reduction 
in the APOB protein and serum cholesterol was observed, and the effect persists for 11 days, indicating 
the importance of the SNALP system77. In a preclinical study, Judge et al. 78 delivered the siRNA 
targeting the PLK1 and KSP in mice using SNALP. This report suggests the usefuln ss of the SNALP in 
delivering the siRNA load to the cancerous cells. Similarly, SNALP was used to deliver the microRNA 
(miR)-199b-5p. Delivery of miR-199b-5p was found to d wnregulate the HES1, and CSC levels in the 
colon ( HT-29, CaCo-2, and SW480), breast (MDA-MB231T, and MCF-7), prostate (PC-3), 
glioblastoma (U-87), and MB (Daoy, ONS-76, and UW-228) cells79. In another antiviral study, Geisbert 
et al. 80 silence the Zaire Ebola virus (ZEBOV) RNA polymerase by delivering siRNA using SNALP in 
guinea pigs model. miR-199b-5p administered using SNALP was found to hamper the proliferation with 
no sign of apoptosis. The effect of SNALP delivery system in the leukemia cell suspension was first 










with polypeptide, PPB was successfully used to deliver siRNAs against heat shock protein82. This data 
indicates that a system like SNALP is very critical in delivering the siRNA to the cancer cells without 
side effects79. 
Recently, protein AXL which is involved in metastasis in both ovarian and uterine cancer was 
silenced by anti-AXL-siRNA using the novel delivery platform called p5RHH. P5RHH is composed of 
the cationic peptide (Melittin). When p5RHH enters the cell, it releases the siRNA upon protonation of 
histidine residue inside the acidic environment of endosomes83. 
4.1.1.2. Atuplex®  
In 2011 a German-based biotech company developed a chemically modified siRNA, called AtuRNAi, 
and a delivery system (Atuple) for in-vivo application. The modified siRNA has the added advantage of 
better resistance towards the nucleases enzymes and higher stability in blood. As it has better stability, it 
is required in less quantity for the same therapeutic effects with a better half-life. SiRNA in this 
modified approach was kept as much natural/non-synthetic as possible by modifying the natural building 
blocks at only 2′ sugar backbone position. No in-vitro and in-vivo induction in the genes associated with 
the inflammatory cytokines, including interferon, was observed. AtuRNAi products are available at a 
lower cost as compared with classical siRNA moleculs. In addition, “silence therapeutics” has also 
developed a novel lipid-based delivery platform forAtuRNAi known as AtuPLEX. This proprietary 
owned complex is made to deliver AtuRNAi to the target cells in vivo. Atuplex composition involves the 
use of fusogenic lipids, which enhance the cellular uptake and assist the endosomal escape. This 
formulation was found very suitable for the delivery of therapeutic siRNA to inhibit the genes involved 
in the angiogenesis process. For specific requirements, “silence therapeutic” also included a PEG 
coating to prevent the interaction with blood protein and hide it from the macrophages. The company 
has around 50 patent applications covering different Atuplex compositions and uses. In one of the 
studies, “silence therapeutics” has reported the preclinical data of their AtuRNAi product called Atu027 
for the treatment of solid tumors84,85.  
4.1.1.3.Rondel® 
Rondel is another important nanotechnology-based delivery system for the siRNA. This system uses the 
electrostatic force of attraction between the negatively charges DNA or RNA molecules and the 
positively charged linear polymer with alternate cyclodextrin molecules85. Adamantane, which is highly 










form the inclusion complex. PEG chains, linked to the inclusion complex on the outside of the 
nanoparticles, acts as a stabilizing agent and prevent its aggregation. A variety of the targeting ligands 
could be conjugated to the distal end of the PEG‒adamantane‒cyclodextrin inclusion complex to enable 
them to selectively link with the cells expressing the protein identified by the ligand. Chitosan is another 
low molecular weight carbohydrate used for the formation of nanoparticles to deliver siRNA. The 
rationale behind the use of such sugar type molecules was to impart the biocompatible character to the 
delivery system, to make them more stable in the biolog cal fluids, and to enhance their transfection 
capabilities85. 
As the name suggests, cyclodextrins are the linked glucose-α (1→4) molecules to form the circular 
basket shape. Hydroxy group of the sugar molecules in this basket topology are directed outwards, 
engulfing the upper and lower rim of the basket. In this configuration, the methinic protons (H-5 and H-
3) are directed towards the inner cavity of the basket. These structural features impart the amphiphilic 
characters, enabling them to charge with the drugs of different physiochemical characters. This 
characteristic is utilized by pharmaceutical companies to develop an efficient drug delivery system for 
the poorly water-soluble, pH liable, or biodegradable drugs86–88.  
Cyclodextrin molecule was selected for the RONDEL complex because of its low immunogenic 
character and toxicity, and its ability to acts as a basket and to form the non-covalent interactions with
the hydrophobic molecules. In 1999, the first case of the cationic polymer cyclodextrin complex 
formation, characterisation, transfection efficiency, and successful delivery of plasmid DNA was 
reported89. To overcome the aggregation of cyclodextrin polymer and pDNA nanoparticles, neutral 
stabilising polymer, PEG was linked with the hydroph bic adamantane to form the stable complex85. 
Suzie Pun et al. 90 proposed the new method for polyplex modification, which utilized the ability of 
cyclodextrin polymer and adamantane to form the inclusion complexes. Non-PEGlyated polyplexes 
were found to aggregate in the salt solution, whereas PEGylated polyplexes remained stable at the 
physiological salt solution. Linking of the targeting ligand to the PEG‒adamantane conjugate further 
facilitated the site-specific receptor-mediated delivery of the complex. Galactosylated PEG adamantane 
inclusion complex was found to have a 10-fold higher efficiency than the un-galactosylated complex90. 
The first in-vivo proof of concept was proposed soon after the introduction of the murine model of 
Ewing’s sarcoma91. The delivery system was composed of the cyclodextrin-containing polycation 










The transferrin protein was used as the targeting ligand to target the transferrin (Tf) receptor. The 
control, i.e., without the transferrin conjugated to the polyplexes, has no antitumor effect91. PEGylated 
inclusion complex linked with transferrin complexed with the luciferase encoding gene when transfected 
to K562 leukaemia cells, resulting in better anti-can er activity as compared to the inclusion complex 
with the linked transferrin protein (Error! Reference source not found.)92,93. Soon after the in-vivo 
success of the siRNA delivery, this concept was firt commercialised by the pharmaceutical company 
(Calandi Pharmaceuticals) in 2008. Human Tf was used at the targeting agent to deliver the siRNA 
(siRNA targeting the M2 subunit of ribonucleotide reductase) using the cyclodextrin polycation delivery 
system (RONDEL) in the non-human primates93. The trade name of the product was CALAA-01. 
This siRNA delivery via transferrin-linked RONALD inhibits tumor growth via RNA interference to 
reduce expression of the M2 subunit of ribonucleotide reductase (R2). Dose-dependent study of siRNA 
revealed the safety profile of the delivery system after the multiple systemic injections94. 
4.1.2. DC-Chol/DOPE cationic liposomes 
Cationic liposomes, composed of DC-Chol and DOPE (DC-Chol/DOPE liposome), were used to deliver 
recombinant genes into established tumors. They are considered as the most efficient vector for the 
transfection of DNA into cells. Nabel et al.95 had effectively delivered the human HLA-B7 gene into 
subcutaneous melanoma in clinical trials using DC-Chol/DOPE liposomes. The findings suggested that 
the transferred HLA-B7 gene was expressed and localized to the site of injection, and no apparent 
toxicity or anti-DNA antibodies was formed, which ind cated the successful delivery of these cationic 
liposomes DC-Chol/DOPE95. In another study, a double-blinded, placebo-controlled trial assessing the 
safety and efficacy of liposome-mediated DNA transfer to the nasal epithelia of cystic fibrosis patients 
using cationic liposomes DC-Chol/DOPE and an expression plasmid containing a human CFTR cDNA 
was conducted96.  
DC-Chol/DOPE transfection system works well only when the lipids are present in the right 
proportion. A ratio of 3:2 or 1:1 of DC-Chol/DOPE in liposomes was found to have maximum 
transfection efficiency97. It was observed that DOPE is a crucial component of the transport system for 
the optimum function98. This system also has a similar issue of stability due to aggregation and immune 
identification, which could be overcame by PEGylation99. Although PEGylation enhances the 










transfection efficiency of the liposomes100. Various other factors could influence transfection 
efficiency75.  
Maitani et al. 98 have prepared three formulations of liposomes in the ratio of 1:0, 3:2, and 1:2 (DC-
Chol: DOPE) to evaluate the effect of chloroquine on endosomal escape. Chloroquine is known to 
increase the endosomal pH, and hence its impact on the formulation was studied. Pretreatment with the 
pH raising agent has shown no effect on formulation having the composition of 1:0 and 3:2, but has a 
profound effect on the formulation with 1:2 ratios in terms of reduced transfection efficiency98. As of 
today, DC-Chol/DOPE cationic liposomes are one of the best carrier systems available for the siRNA 
delivery to the cancer cells. But this has its own drawbacks, like not suitable for systematic delivery 
because of the aggregate’s formation with blood protein. To overcome this issue, Lee et al. 101 have 
PEGylated the DC-Chol/DOPE cationic liposomes for kinesin spindle protein siRNA delivery to the 
cancer cells and to check its fate on systemic delivery. PEGylated composition was found to have a 
longer half-life in blood and enhance tumor accumulation as compared to non-PEGyated lipoplexes. 
PEGylated siRNA delivery has better silencing effects than the non-PEGylated siRNA and at the same 
time they  remained hidden from the immune system of ice. These results indicated that in the coming 
days, DC-Chol/DOPE is better placed to deliver the siRNA via systemic delivery101. Liu et al.102 have 
used DC-Chol/DOPE cationic liposomes system to deliver the siRNA against the ferritin to check its 
effects on iron homeostasis in glioma cells and chemosensitivity. On intratumoral injections of 
liposomes-containing ferritin siRNA, around 80% of ferritin protein inhibition was observed in two 
days. This decrease in the ferritin level was positively correlated with the enhanced chemosensitivity 
towards the carmustine102. To overcome the short-term gene silencing effects of iRNA, Seraj et al. 103 
have designed Eg5shRNA-expressing plasmids to produce Eg5 hairpin RNA. To deliver this RNA, they 
used PEGylated DC-Chol/DOPE cationic liposomes and observed that the single systemic dose of Eg5 
hairpin RNA expressing plasmid had long term Eg5 gene silencing effect in tumor-bearing mice. This 
system was also found to have no immunogenicity103. A study was reported by Tseng et al.104 and  found 
out the impact of disaccharides on the internalisation of plasmid on different vectors. Increased cellular 
delivery was observed when co-formulated with disacch rides104. The ability of DC-Chol/cholesterol 
liposomes to carry pDNA into 293T cells was investiga ed. A formulation containing cholesterol was 
found to have not only uniform particle size and lower turbidity, but also better transfection 
efficiency105,106. Among stimuli-sensitive cationic liposomes, pH-sen itive has very low transfection 










complexes containing DC-Chol and DOPE liposomes and pH-sensitive liposomes composed of CHEMS 
and DOPE, and evaluated the influence of various factors on pDNA transfection efficiency. All DC-
Chol/DOPE liposome/pDNA and pH-sensitive liposome complexes showed similar pH sensitivity. 107. 
DC-Chol/DOPE cationic liposomes are optimised for transfection in the absence of serum. Further 
understanding of the difference between such composition  will lead to the better designing of the DC-
Chol-DOPE liposomes. Transfection efficiency was further found to increase with the addition of 
protamine in the formulation108. Kisoon et al.109 in one of their report, described the synthesis of the 
CHOL derivative 3β[N-(N′N′,N′-trimethylamino-propane)-carbamoyl] cholesterol, in which a 
propylamidooxy spacer separated the cationic trimethylamino head group from the hydrophobic and 
rigid cholesteryl ring system, and used them to make liposomes with an equimolar ratio of DOPE. The 
CHOL derivative, in combination with DOPE was found to provide better protection to the pDNA 
against the nuclease digestion and has better transfection efficiency109. To study the effect of PEGylation 
on gene silencing, Hattori et al. 110 used four types of cationic CHOL derivatives and three types of 
dialkyl or trialkyl cationic lipids and prepared seven types of PEGylated cationic lipoplexes that 
contained 1 % (mol/mol) PEG2000-DSPE. The PEGylation helped to reduce the aggregation with the 
blood components on intravenous injection. PEGylated cationic lipoplexes with N,N-dimethyl-N-
octadecyloctadecan-1-aminium bromide has shown significa t gene silencing effects in the lungs110. 
Overall, this study also revealed that 1 % (mol/mol) of PEG and variation in cationic lipids severely 
affected the gene silencing effects of siRNA. The sel ction of cationic lipids is critical for the success of 
the PEGylated cationic liposomes110. 
Despite the success of cationic lipids, hurdles like endosomal escape, cytosolic delivery, and lipid 
toxicity are still restricting the exploration of its full potential. To address this critical challeng , 
Lechanteur et al.111,112 prepared four different cationic liposomal formulations using DOTAP and DC-
CHOL, and a different ratio of CHOL and DOPE. SiRNA was complexed with liposomes at six 
different siRNA/lipid molar ratios. The group confirmed that the nature of the lipid and lipid/siRNA 
ratio severely affected the cytotoxicity. It was observed that the cell‒cell viability was reduced by 70% 
with liposomes composed of DOTAP/CHOL/DOPE (1/0.75/0. ) at a lipid/siRNA ratio of ten, whereas, 
at the molar ratio (Lipid/siRNA) of 2.5, the same formulation was found to be safe. For all the 










Overall, for the successful development of CHOL/DOPE lipoplexes, it is not only essential to select 
the proper cationic lipids, but the ratio of lipids to siRNA plays a crucial role. Another critical point to 
be noted is that the acidity of exosomes plays a vital role in the exosomal escape. Hence it is essential to 
stress the proper selection of pH-sensitive lipids.  
 
5. Lipid-protamine‒DNA/hyaluronic acid (LPD/LPH) nanoparticles 
The effort to improve the transfection efficacy of the cationic liposomes is focused on the development 
of the new cationic lipids and polymers. Theoretically, cationic lipids or polymers having multiple 
positive charges shall have better transfection effici ncy as compared to the monovalent cationic lipids. 
So the increase in the overall negative charges on the RNA or DNA molecules with the simultaneous 
increase in the positive charges on the cationic lipids could have better electrostatic charges and 
transfection efficiency113. Research in this area is mostly based on the trail, and hence enhancing the 
transfection efficiency of the existing cationic polymers is desirable.  
One of the significant disadvantages of the DC-CHOL liposomes is its low transfection efficiency 
because of the larger nucleic acid/liposome complexes. The size of this complex at optimum nucleic 
acid to liposome ratio varies between 0.6‒1 μm95. Liposomal complex aggregates to form the larger 
particles. However, several measured are under consideration to prevent aggregation. For example, in a 
clinical trial for malignancy treatment, DMRIE/DOPE, a cationic liposome was prepared, which does 
not aggregate to form the larger particles114. DC-CHOL/DOP liposome was prepared to transfect the 
CFTR gene and restores its activity in cystic fibrosis patients. This liposome has shown no sign of 
aggregation and achieved maximum transfection with al ered transfection protocol. DNA/Liposome 
complex was prepared at high pH 8 to prevent the aggregation96. 
Wagner et al. 115 have shown that the shape of the DNA-Liposome complex lays a crucial role in 
the receptor-mediated endocytosis of the targeted ligand linked liposomes. In this transfection system, 
transferrin conjugated to the liposome acted as a targe ing ligand, and polycation part acted as the 
counterpart for the electrostatic link with the negatively charged transferrin molecule. Polycation also 
squeezed the DNA molecules to form the doughnut-shaped delivery system. The degree of DNA 
condensation was found to be directly linked with the transfection efficiency. In this study, it was 
revealed that replacement of the large portion of the ransferrin polylysine with free polylysine, 










enhance transfection efficiency. It was also observed that protamine and histone could also be replaced 
with the polycationic part to get condensation of the DNA115. 
Gao et al.116 tested some high molecular weight cationic polymers to check their effects on the 
transfection efficiency of the cationic liposomes. Poly(L-lysine), poly(L-ornithine), and poly(D-lysine) 
and polybrene were found to be equally effective in potentiating the transfection efficiency. However, 
the treatment of cationic liposomes with poly(D-lysine) or polybrene has led to deleterious effects on the 
cell, indicating that poly(L-lysine) or protamine are the safer alternatives to enhance the transfecting 
effect of the cationic liposomes. Gao et al. 117 again in 2013 developed liposome‒polycation‒DNA 
complex functionalised with anti-epidermal growth factor receptor Fab' antibody to target the epidermal 
growth factor receptor of the hepatocyte.  
Clinical application of LPD to deliver siRNA to target C-MYC, MDM2, and VEGF by LPD was 
investigated. Silencing of these genes using LPD deliver d siRNA lead to the reduction in the metastasi  
events of B16F10 melanoma cells in vivo. This study indicates that the LDH could be the most desirable 
tool to deliver the siRNAs to the cancer cells and could be the base for the future drug delivery 
system118. 
The concept was proved valid with the development of PEGylated LPD (LPD‒PEG‒anisamide) 
nanoparticles, which boosted the siRNA delivery to cancer cells and simultaneous silencing of the 
associated gene, leading to the cancer cell growth inhibition119. SiRNA against the survivin, delivered by 
LPD‒PEG‒AA was not only found to induce the apoptosis process but also sensitize the cancer cells 
towards the cisplatin64. 
Similarly, siRNA against EGFR delivered by LPD‒PEG‒AA was found to inhibit the EGFR 
expression in the cancer cells along with enhancing apoptosis120. These studies indicate that the targeted 
liposomes could be a powerful tool to deliver siRNA to the cancer cells. One of the most critical 
characters of the efficient delivery system is its inertness towards the immune system. On this front LPD
system has little toxicity and inertness as confirmed by Chono et al73. The group has developed an LPD 
nanosystem to deliver siRNA systematically to the cancer cells. Cationic liposomes formed by mixing 
protamine, hyaluronic acid , and siRNA were coated with the cationic polymers. The complex thus 
formed again modified by adding lipids DSPE‒PEG or by adding targeted PEGylated lipids like DSPE‒










liposome system developed had higher loading and transfection efficacy along with the low 
immunotoxicity in the dose range of 0.15–1.2 mg siRNA/kg73. 
Two important issues of the siRNA therapy and delivery system are the 1) non-specific delivery, 
including poor uptake by the cancer cells, and 2) unfavorable pharmacokinetics, including nucleases 
degradation and rapid clearance from the systematic circulation. Both issues were tried to be resolved by 
Chen et al.121 by delivering siRNA and DOX together. The group developed LPD nanoparticles for the 
site-specific delivery of the siRNA to the cancer cll of the mice by modifying LPD system with the 
NGR (aspargine–glycine–arginine) peptide. NGR is a lig nd for the aminopeptidase N (CD13), mostly 
overexpressed in the tumor cells. The system was found to be efficient in delivering the siRNA to the 
cells and successfully down-regulate the target gene in HT-1080 cells121. 
Chen et al.122 confirmed that the c-MYC siRNA could sensitize the cancer cells towards the 
paclitaxel. PEGlyation plays a vital role in the stability of the nanoparticles; hence, to determine th
efficiency of the PEG linker, Deng et al. 123 compared the siRNA delivery efficiency of DSPE-PEG-
COOH or DSPE-PEG-MAL derivatives linked with the anti-EGFR Fab’ via a post-insertion approach. 
Immuno LPD, where anti-EGFR Fab’ linked through theDSPE-PEG-MAL conjugation, was found to 
be more efficient in delivering the siRNA to the target cell than the nanoparticles where anti-EGFR Fab’  
was linked via DSPE-PEG-COOH linkage123. 
Overall, siRNA is the crucial tool in gene therapy, and its delivery to the target cell is a critical 
barrier to overcome. A combination of siRNA and chemotherapeutic agents has recently achieved 
tremendous attention because of their synergistic ac on, better anti-cancer activity, low side effects, and 
fewer incidence of the drug resistance emergence. I combination therapy, siRNA and chemotherapeutic 
agents must have the synergistic action and should not have the antagonistic impact. To make cancer 
therapy more specific and safer, liposomal delivery using the targeting ligand significantly improves the
efficiency of chemo and gene therapy. LPD not only offers the opportunity of delivering the 
siRNA/chemotherapeutic agents, but can also deliver the siRNA/therapeutic agent specifically to cancer 
cells if modified to link them with the targeting li and, thereby avoiding the side effects. The following 
Error! Reference source not found.124–129 represents the various valuable work carried out in he 
chemotherapeutic delivery to the cancer cells using LPDs. 










Despite the LPD success in delivering therapeutic siRNA to the cancer cells, improvement in terms of 
cellular uptake and bioavailability is required. LPC in terms of assembly is similar to the LPD except 
that the core of LPD is substituted with siRNA trapped nano-size calcium phosphate precipitate prepared 
by water-in-oil micro-emulsions130. This particular system was first reported by Li et al.130 in 2010, 
describing its utility in siRNA delivery. It was hypothesised that the inorganic ion would degrade inside 
the acidic pH of the exosome, leading to swelling ad bursting, and ultimately release siRNA trapped 
inside it. PEGylation was further carried out, and anisamide, which is a ligand for the sigma-1 receptor, 
was conjugated. In their study, siRNA against luciferase was used as a model to predict the gene 
silencing effect of this new carrier in H-460 cells. Nanoparticles conjugated with the targeting agent, 
anisamide, have shown better gene silencing effects than the unconjugated. This formulation was also 
found better when compared with LPD.  
In LPD, which was reported by the same group, the DNA protamine complex was wrapped by the 
cationic liposome to form the positively charged particles. The positively charged particle then was 
further modified to include PEG and target ligands to impart site-specific delivery and better circulation 
time. This system, though successful, needed improvement in terms of endosomal escape. To overcome 
this issue, LCP nanoparticles were proposed. The 1st generation LCP (LCP-I) was made up of citrate-
stabilized calcium phosphate core wrapped by cationic liposomes. The particle thus formed are suitable 
for the post-insertion of PEG and ligand conjugation131. The process of purification of LCP-I was 
tedious; hence, second generation LCP-II was proposed by Huang et al.131 (Error! Reference source 
not found.). In LCP-II, a lipid called DOPA was introduced ins de the core to stabilize the nanocarriers. 
A similar reverse microemulsion method was used for their preparation. However, the sodium citrate 
was replaced with DOPA. In both LCP-I and LCP-II, the entrapment of siRNA or DNA occurred at the 
precipitation step. Other than siRNA, DNA chemotherapeutic agents having phosphate groups are the 
good candidates for LCP encapsulation131. 
LCP is now the best-known nanocarriers for its efficiency in delivering the siRNA to the cancer 
cells. This efficiency is related to the fact that c lcium and phosphate rapidly dissolve at the acidic pH of 
endosomes. This causes endosomal degradation, releasing the siRNA into the cytoplasm. Several 
modifications are still underway to modify this system for better delivery property. Maitra et al.132 have 
reported the preparation of calcium phosphate nanoparticles using a reverse microemulsion 










creating a severe stability issue. To overcome this issue, Sokolova et al.133 have developed a rapid 
precipitation method of calcium phosphate nanocarrier formation. This colloidal system has shown 
better stability over a period of time. To further xplore the efficacy of the calcium phosphate 
nanoparticle, Liu et al.134 have developed the nanocarriers of 23.5‒ 4.5 nm in diameters. This calcium 
phosphate system was found to be very efficient in delivering the DNA molecules with a very high 
transfection rate at the same time protecting DNA from degradation134. This system was also used to 
deliver DNA molecules by transfecting plasmid DNA135. Polyacrylic acid/calcium phosphate 
nanoparticles were reported by Wang et al.136 for delivering drug to the cancer cells. Radionuclide-like 
177Lu and 111In were also successfully encapsulated inside the LCP along with the chemotherapeutic 
agents137. 
Over the years, the LCP has shown success not only in delivering the siRNA molecules but also 
other treatment and imaging agents. In the future, there are many opportunities to combine the efficien y 
of LCP with other carriers for the simultaneous delivery of therapeutic and imaging agents.  
5.2. Inorganic nanoparticles 
Inorganic nanoparticles are most extensively used a an imaging probe because of their unique chemical 
and physical features that arise from their nanoscale size138. Several nanoparticle probes for imaging 
were developed using their magnetic, optical, and X-ray attenuation properties. Elements like gold, 
bismuth, and silver have been successfully used to contrast images of CT scans because of their high X-
ray attenuation properties139–141. Similarly, inorganic elements and compounds like silver, gold, iron 
oxide, and silica were studied to analyze their utilization in drug delivery systems142,143. Only a few of 
these nanoparticle has reached to the advance stage, and most of them are in the initial phase of clini al 
development.  
Moreover, silver and gold nanoparticles possess the peculiar optical property of surface plasmon 
resonance, which makes them different for the liposomes, micelles, and dendrimers144. Surface plasmon 
resonance is the basic principle behind several color-based biosensor techniques. It is an oscillation of 
conduction electrons at the interface between negative nd positive permittivity material stimulated by
incident light144. Surface plasmon resonance helps to measure the adsorption of materials on the planer 
surface of metal like gold and silver. Furthermore, b cause of their biocompatibility, they are now being 










Drugs can be conjugated with the gold nanoparticles via covalent or electrostatic bonding and could 
be released inside the cells by external or biological stimuli145. Silver has reported antibacterial activity; 
however, few reports have been published confirming the use of silver nanoparticles for drug delivery. 
Prusty et al.146 developed stimuli-responsive polyacrylamide/dextran nanohydrogels composites material 
by in situ polymerization technique with incorporated reduced nanosilver. Jain et al.147 prepared iron 
oxide nanoparticles to target the antracyclinic antibiotic violamycine B1 to breast cancer. Cytotoxicity 
and the anti-proliferation effects of nanoparticles were tested in vitro on the breast adenocarcinoma cell 
line (MCF-7)147. Ngamcherdtrakul et al.148 developed the 47 nm mesoporous silica nanoparticle cor  
coated with a crosslinked polyethyleneimine–polyethlene-glycol copolymer, conjugated with anti-
human epidermal growth factor receptor type 2 siRNA and trastuzumab (a monoclonal antibody against 
human epidermal growth factor receptor). This nanoprticle was developed to enhance the half-life of 
siRNA in blood and DNA silencing effect of siRNA by explicitly targeting the cancer cells148. 
Overall, the inorganic particles provide a useful medium for the development of the delivery 
vehicle for the siRNA149. They offer a high surface area to volume ratio, which ensures the high 
conjugation of siRNA and hence better loading. A crucial key to the success of the inorganic 
nanoparticle delivery system is the flexible surface chemistry, which provides the means to overcome 
the hurdles of safe siRNA delivery150. Additionally, it is easy to track the siRNA delivery to the cells 
because of their unique physical and chemical properties151. 
Among the inorganic nanoparticles, because of their in tness, nontoxicity, and biocompatibility 
properties, gold nanoparticles are the most widely studied for siRNA delivery151. Strong interaction 
between sulfur and gold (S‒Au bond) elements helps to conjugate the biological and synthetic 
compounds on to the surface of gold nanoparticles152. S‒Au bond is composed of around 35% of partial 
covalent and 64% electrostatic characters153. An energy decomposition analysis indicated that gold had a 
greater covalent character with sulfur ligands relative to Cu and Ag154. Covalent linking to the gold 
nanoparticles did not affect and inhibit siRNA´s biological activity155. 
In recent times the research interest is grown significa tly in polyvalent oligonucleotide 
nanoparticle conjugates, which consist of the core f the 2‒250 nm, and several strands of 
oligonucleotide covalently conjugated to it156. The polyvalent oligonucleotide nanoparticle conjugates 
possess unique properties like cooperative binding, hi her complementary strand binding, catalytic 










intracellular stability and resistance toward the nuclease enzymes, which makes them the potential 
candidate for gene silencing157–161. Seferos et al.156 examined the polyvalent oligonucleotide 
nanoparticle conjugates and explained the enzymatic resistance and intracellular stability. For stability 
study, they prepared 1 nm gold nanoparticles and functionalized them with the 20 base pair long 
oligonucleotides linked via 10 base pair linker DNA and propylthiol anchor156. The thick coat of 
oligonucleotides on the surface of nanoparticles was found to protect them against the enzymatic 
degradation of nucleases enzyme.  
For conjugation, thiolate oligonucleotide reacted with the citrated-capped gold nanoparticles. 
During the reaction, oligonucleotide ligands displaced the citrate group of the gold nanoparticles and 
formed the gold thiol bond. Sodium chloride could be used to stabilize the charge repulsion, thereby 
allowing the more oligonucleotides to conjugate on the surface to create the dense monolayer coat. 
Around 250 nucleotides could be comfortably conjugate on the surface area of the gold nanoparticle of 
15 nm size to give rise to polyvalent complex161. This conjugation method was successfully used to 
conjugate the oligonucleotide to the nanoparticles of the size between 2 to 250 nm162. Irrespective of the 
high negative charge, which could prevent the cellular uptake, polyvalent oligonucleotide gold 
nanoparticles have remarkable uptake, as seen in more than 50 different cell lines163,164. Cellular uptake 
was found to be the function of the oligonucleotide density on the nanoparticles; higher density was 
found to support the more efficient delivery157,160. The uptake of anionic nanoparticles (oligonucleotide 
conjugated) is attributed to the strong binding with the scavenger receptor, which is an essential protein 
involved in the receptor-mediated membrane transport system. The superfamily of the scavenger 
receptor proteins could bind different types of ligands, including polyanionic compounds like 
lipoproteins, apoptotic cells, cholesterol ester, phospholipids, proteoglycans, ferritin, and 
carbohydrates165. This recognition of the wide range of compounds allows the scavenger proteins to play 
a crucial role in pathology and homeostasis. Scavenger receptor protein undergoes endocytosis after 
binding to the ligands. This mechanism provides the universal mechanism of delivery to the healthy and
disease cells. Targeted delivery to the cells over-expressing the surface proteins is also possible by 
conjugating the antibody against such protein to the polyvalent oligonucleotide gold nanoparticles166. 
Hao et al.167 used synthetic tumor suppressor microRNA (miR-205) to conjugate with the 
oligonucleotide gold nanoparticles. These miRNA-conjugated polyvalent oligonucleotide gold 









developed the delivery system for siRNA by complexing the thiolated siRNA with the gold nanoparticle 
to which poly(ethylene glycol)-bpoly(2-(N,N-dimethylamino)ethyl methacrylate) was conjugated. 
siRNA was found to significantly suppress the expression of luciferase expression in HuH cell line. 
Giljohann et al.169 reported the RNase-free polyvalent siRNA gold nanoparticles to silence the gene in 
HeLa cells. This siRNA-conjugated gold nanoparticle was found to have the six-time longer shelf life in 
the serum than their RNA duplex counterparts. The functionalization with siRNA leads to the 
development of nanoparticle with better cellular uptake without the need for chemical modifications or 
the use of other transfection medium169. 
Local suppression of the genes in the skin presents the unique challenge of negative charge of large 
molecules like siRNA delivery. Zheng et al.170 reported the spherical nucleic acid nanoparticle 
conjugates, gold cores with conjugated siRNA. The siRNA conjugated nanoparticles were found to 
freely pass through 100% of skin cells in vitro, mouse and human epidermis within hours after 
application170. When siRNA against EGFR was delivered using this system locally to the skin of a 
hairless mouse, complete inhibition of EGFR expression and downstream ERK phosphorylation were 
observed170. 
The success of siRNA delivery system depends on the endosomal escape, and this is also true in the 
case of the siRNA-conjugated inorganic nanoparticles. Massich et al.171 successfully demonstrated the 
endosomal escape of the siRNA after 4 h from the polyvalent nucleotide gold nanoparticles by tagging 
them with cyanine 5.  
As discussed earlier, various cationic materials like pids and polymers were used to condense the 
siRNA to form the nanoparticles. Additionally, various functionalized nanomaterials, like carbon 
nanotubes, iron oxide nanoparticles and gold nanoparticles, were also used to condense the siRNA for 
delivery172–174. These materials were also found to reduce toxicity as compared to the polymers175. 
Compared to the plasmid size DNA, siRNA usually hasles  efficient interactions with the cationic 
materials because of the small size. Hence, siRNA requi ed a high concentration of such materials for 
efficient compression or a material with high cationic characters. To overcome this issue, gold 
nanoparticles with conjugated cationic ligands were us d for better interactions. Kim et al.175 reported 
the gold nanoparticles conjugated with dendritic PEI-like ligands to enhance the cationic characters. The
siRNA-conjugated superamolecule developed using this protocol was found to have good gene 










developed coated gold nanoparticles with poly(ethylnimine) to produce the poly(ethylenimine)‒gold 
nanoparticles complex. The complex was further conjugated with the targeting ligand anisamide to 
produce a cancer cell-targeted siRNA delivery system. Anisamids is the ligand for the sigma receptor, 
which is overexpressed on prostate cancer cells176. To silence the ROR1 oncogene, which is 
overexpressed in different cancers, Ahwazi et al.177 immobilized HIV‐1 TAT peptide on gold 
nanoparticles and conjugated the particles with the ROR1‒siRNA for the potential breast cancer 
treatment. In an alternative approach Shirazi et al. 178 synthesized and conjugated homochiral L-cyclic 
peptide to the gold nanoparticle to deliver the siRNA in HeLa cells. For the Dengue treatment, Paul et 
al.179 conjugated anti-DENV siRNAs with gold nanoparticles (AuNPs) and tested them in vitro.  
Overall, among inorganic materials, gold nanoparticles have shown the potential to be the 
preferential delivery agent for the siRNA. Reports of various ligands, like cell-penetrating peptides, 
protein, antibody covalently linked to the gold nanoparticles, are available. These ligands have shown 
promising results for siRNA delivery7,180. The siRNA conjugated to the gold nanoparticles ha shown 
resistance towards the nuclease-based degradation and promoted the timely endosomal release. 
However, such ligand‒gold nanoparticles lack serum stability and have a very short self-life, which 
prevents its long-lasting gene silencing effect. S‒Au covalent chemistry is the most direct method to 
conjugate siRNA to gold nanoparticles. Oishi et al.168. used S‒Au chemistry to conjugate the siRNA to 
gold nanoparticles. They prepared 15 nm gold nanoparticles and conjugated it with S–PEG5000–
PAMA7500 polymer followed by linking them with the thiolated siRNA. Jensen et al.
181 extended this 
concept to produce spherical nucleic acid-linked gold nanoparticles. They used this system to 
knockdown the Bcl2L12 mRNA using the siRNA against it in glioma cells181. Gold nanoparticles 
covalently linked with the siRNA was further coated with streptavidin layer to attach cell-penetrating 
peptides through biotin-streptavidin ligation182. Gold nanoparticles are also developed into the advanced 
platform for targeted delivery. For example, thiol–siRNA and Arg‒Gly‒Asp were simultaneously 
conjugated to the gold nanoparticles to carry the siRNA to the lung tumor cells in the murine model.  
The more convenient conjugation method to conjugate the siRNA is the non-covalent linking. Non-
covalent linking is facilitated by the electrostatic attraction between the negatively charged siRNA and 
positively charged nanoparticles. For example, Kim et al.175 reported the gold nanoparticles conjugated 
with dendritic PEI-like ligands to enhance the cationic characters, which were letter conjugated with the 










the gold nanoparticles, which was later used to entrap the siRNA for delivery183. One advanced method 
of siRNA conjugations is layer by layer coating of gold nanoparticles with alternate layers of cationic 
polymer and siRNA to give rise to the coat of gold nanoparticle‒cationic polymer‒siRNA‒cationic 
polymer. Elbakry et al.184 developed the gold nanoparticle using layer by layer approach and further 
investigated its usefulness in siRNA delivery. Similarly, Lee et al. 186 for hyaluronic receptor-mediated 
siRNA delivery have developed the cysteamine-modifie  gold nanoparticles layered with siRNA‒
polyethyleneimine‒hyaluronic acid. For extended gene silencing and lower toxicity, Lee et al.186 have 
used protease degradable polylysine as a biodegradable biopolymer. They conjugated the gold 
nanoparticles with the siRNA, which were then coated with the polylysine. The layer of poly-lysin was 
then degraded by the lysosomal cathepsin B enzyme ensuring the extended-release of siRNA185,186. 
Inorganic nanoparticles have provided the unique stage for the effective delivery of siRNA to the 
cancer cells. Delivery of siRNA using organic nanoparticles can be fine-tuned by modifying the 
nanoparticle surface. As discussed, inorganic nanoprticles possess the unique physical and optical 
properties which could be used to track the fate of such particles inside the body. The potential of 
organic potential is not only limited to the siRNA delivery but could be used for diagnostic purpose. 
Despite the several advantages, several hurdles needed to be overcome to translate the lab research to 
the patients on the bed. For clinical translation, precise information about the safest route of 
administration, toxicity, immune response, long and sustained release of the siRNA is required. 
Overcoming these hurdles will need a better understanding of the central aspects of inorganic 
nanoparticle relation with living systems. Research on such interaction will ensure the faster translation 
of lab research to the clinical trials. 
5.3. Micelles for siRNA delivery 
Polymeric micelles are another nanocarrier system which has attracted remarkable attention as a 
potential carrier to deliver siRNA to the cancer cells. Micelles are made up of the blocks of the two or 
more polymers having an opposite affinity towards the same solvent. Thus, polymers of the micelles 
have amphiphilic characters. These amphiphilic block polymers, when suspended in a solvent, organized 
themselves to form the micelles depending upon the block affinity towards the solvent. If the diblock 
polymer suspends in the aqueous phase, the hydrophobic end of the polymer attempts to stay away from 









aqueous phase forming the micelle shell. The formation of micelles only occurs at the concentration 
above the critical micelles concentration (CMC). Generally, micelles forming at the lower CMC are 
more stable and better to deliver the siRNA to the cancer cells. Polymers with high hydrophobicity 
characters exhibit better stability due to the lower CMC. In aqueous solution, less water-soluble 
compounds get trapped inside the hydrophobic core of the micelles, whereas the compounds with the 
higher hydrophilic characters remain in the intermediate layer187.  
Micelles could be divided into two broad categories (Error! Reference source not found.): 1) 
formed from the direct linking of the PEG through non-degradable linkages to siRNA to form the PEG‒
siRNA complex; 2) formed from the direct condensation of the siRNA with the block amphiphilic 
polymers containing the polycations followed by micellization of block copolymer/siRNA complex188. 
The advantage of the polymeric micelles is their ability to solubilize the water-insoluble 
compounds inside its core. This system helps to enhance the bioavailability of the drugs, the full 
potential of which is difficult to explore because of unfavorable pharmaceutical characters. Due to the 
low water solubility, it is sometimes challenging to achieve the complete therapeutic outcome of the 
compound. Most of the anticancer drugs are polycycli  ompounds, hence has to face the same 
pharmaceutical challenges. If such drugs are administered via the parenteral route, the chances of 
building aggregates large enough to block small capillaries are very high189. Polymeric micelles could 
not only enhance bioavailability by inhibiting rapid extraction and solubilizing compounds at the core 
but also deliver them at the site of action if they are conjugated with the targeting ligands. Another 
distinct advantage of the micelles is its size (10‒100 nm), which is small enough to remain in the 
circulatory system by avoiding the mononuclear phagocytic system and large enough to prevent fast 
renal clearance190. Further, leaky vasculature of the tumor helps the higher accumulation of the micelles 
via EPR effect191. Polymeric micelles formed at the lower CMC offer higher stability even if diluted in 
the higher volume of the body fluids, which allows the hydrophobic compounds to remain inside the 
core being protected for a longer time.  
5.3.1 Passive and active micelles targeting  
Polymeric micelles are 10 to 100 nm diameter nanocarriers. The hydrophobic core of the micelles 
carries the water-insoluble drugs, whereas the hydrophilic component helps to hide the assembly from 
RES and enhances its blood circulation time. This property allows micelles to accumulate passively 










of the block copolymer chemistry permits the easy alter tion of micelles structure according to the 
physical and chemical properties of the drug, ligand conjugation, tumor environment, and sensitiveness 
to external and internal stimuli. The features and functions of active and passive micelles targeting are 
summarized in Error! Reference source not found.192–198. 
 
5.3.2. Stimuli-responsive polymeric micelles 
Distinct characters of the cancer cells or tumor microenvironment act as a stimulus of the drug releas. 
In general, micelles made for such a stimulus carry the drug in one environment (extracellular or in 
normal tissue environment) and release it when such mi elles enter in the distinct environment of the 
tumor and cancerous cells199. Polymeric diblocks could be used to prepare such micelles to respond to 
the intrinsic (redox potential, enzymes, cofactors, enzymatic products, and pH) or extrinsic stimuli 
(ultrasound, external magnetic field, temperature, and light). Stimulus-sensitive micelles release the drug 
load after the structural change/destruction in respon e to the external or internal stimuli. These stimuli 
generally lead to the destruction of the micelles via polymerization, aggregation, disintegration and 
isomerization, etc.199. The most common stimuli-responsive micelles are discussed in Error! Reference 
source not found.187,200–204.
5.3.3. Recent multifunctional micelles delivery of siRNA to cancer cells 
Recent approaches allow the integration of the bestof different physical and chemical characters into 
single multifunctional micelles. When different functionalities were combining in a new hybrid micelle 
where each component is working in complete harmony a d coordination with the other to give the 
simultaneous or sequential drugs/siRNA/diagnostic agents, such hybrid micelles are termed as 
multifunctional micelles. Thus, the ideal multifunction micelles could not only deliver the therapeutic 
agents but, if required, should also be able to deliver the diagnostic agents. Cancer, which is a 
multifactorial disease, is not only difficult to treat, but the perfect diagnosis is challenging. Recent 
advances in molecular therapies have developed very selective treatments. However, some of the cancer 
cells remain undetected, develop resistance over the period of time, and lead to therapy failure. Cancer 
cells and tumor environment have several distinct characters which differentiate them from the normal 
cells and tissue microenvironment205, which includes several deregulated protein expression, pH, distinct 










approach. Considering all the distinct characters of the cancer cells and the versatility of the micelles to 
carry the different load, it becomes imperative to use multifunctional micelles for the treatment. 
Although incorporating all the ideal characters of drug delivery into one single vehicle is difficult, a 
blending of two or more characters is possible and is necessary for the cancer treatment. In recent times 
the research focused on the development of the multifunc ional micelles to enhance the delivery 
efficiency, minimized the side effects, and simultaneous delivery of diagnostic agents. The recently 
reported multifunctional approaches are discussed in Error! Reference source not found.206–228.  
Based on the literature review, the two common strategies employed to make the polymeric 
micelles involves: 1) direct conjugation of siRNA to hydrophilic (PEG) or hydrophobic (lipids) via non-
degradable or degradable linkages. This is followed by their exposure to the polycations to form the 
micellar structures called polyion complex micelles(PIC). Poly(aspartic acid) or poly(L-lysine) or PEI is 
the most commonly used polyion segment229. 2) SiRNAs are complexed with an amphiphilic block 
copolymer having polycations segments followed by the micellization of the complex230. Nanocarriers, 
including micelles, cross the cell membrane by the endocytosis process. One of the significant causes of 
concern is the endosomal escape after endocytosis. SiRNA inside the endosomes are nothing better than 
outside the cells. They need to escape out of the endosomes to avoid the lysosome’s lower pH (pH ~4.5) 
and potential degradation. Endosomal escape makes the iRNA available in the cytosol to form the 
silencing complex. Cationic polymers are hence incorporated in the polymeric micelles, which release 
siRNA by disturbing the endosomes. Some polymeric mi elles also included pH-sensitive polymers, 
which, when exposed to the endosomal pH, disrupt the endosomes and release siRNAs in the cytosol. 
Some micelles formulations utilized polymers, which, when exposed to the external stimuli like light or 
magnetic fields, destabilized the endosomes to releas  the siRNAs. Considering the current literature 
discussed in this section, we can assume that the multifunctional polymeric micelles are one of the front 
runners to establish itself as the best delivery option to carry siRNA inside the cancer cells. 
Multifunctional micelles are a combination of the different functionalities bought together to develop the 
ideal delivery platform. However, the basic architecture of modern micelles is getting more complex, 
which not only could create the reproducibility problem, but also high siRNA entrapment and better 
cellular uptake will be an issue. Such complexity could also become the hurdle in real-life clinical 
utilization, and finally, the approvals from the various regulatory bodies will be the challenge231. 










Until now, the unavailability of the proper delivery vehicle has restricted the clinical application of 
siRNA. siRNAs, which are the double-stranded negative charge molecules with hydrophilic characters, 
are relatively impermeable to the cell membrane. Chemical modifications to change the characteristics 
of the siRNA are required to cargo them to the cytosol. Such modifications could adversely affect the 
binding properties, and in some cases, siRNA could even irreversibly change to an inactive molecule. As 
discussed, various lipids and polymer-based delivery hicles systems based on the nanotechnology 
platform were developed. Among them, the polymer-based delivery system received wider acceptance. 
Different gene-based products like protein, nucleic acids, peptides were delivered to the cells using 
polymer-based delivery systems. 
We have already discussed the lipid-based strategies and the impressive research that took place to 
develop them into a potential delivery candidate. Polymers also have a potential role to play in the 
cytosolic delivery of proteins, DNA, and siRNA232–235. Various polymer compositions with different 
topology could be synthesized using techniques like atom transfer radical polymerization, reversible 
addition-fragmentation chain transfer polymerization, and ring-opening metathesis polymerization. At 
the same time, they can be readily derivatized by adding different functional groups to suit the 
applications. Moreover, the polymers with positive charge have developed a special interest in the 
delivery of siRNA. They not only form the reversible complex with the negatively charged RNA 
molecules but, but also facilitate the higher cellular uptake and endosomal escape. The stable reversible 
complex formation of siRNA with polymers is the challenge that needs to meet on a priority basis. 
Cationic polymers are already explored for their capability to carry the gene to the cell236–238. Due to the 
high negative charges on the siRNA, the cationic polymers bind and condense into the nanoparticles via 
ionic interactions. Even with the advancement in the polymers science, its use is restricted because of 
the limited number of binding sites available on the siRNA molecules. The limited interactions between 
the polymers and siRNA molecules lead to the formation of relatively unstable nanoparticles. This 
problem could be overcome with the utilization of hyperbranched polymers with large molecular weight 
and dendritic topology. Such polymers significantly enhance the transfection efficiency but at the cost of 
toxicity. For example, Yang et al.239 reported a nanoparticle system composed of high molecular weight 
linear PEI condensed with DNA and coated by a shell of polyethyleneglycol-modified (PEGylated) low 
molecular weight linear PEI. Compared with the commercial delivery system, a 16,000-fold increase in 
the transfection efficiency was observed. Although the nanoparticles offer substantial advantages of 










weight polymers is still in the initial phase of development. Several attempts have been made to develop 
polymer with high transfection efficiency and lower toxicity240–242. 
As discussed, intracellular delivery of the siRNA to the normal and cancer cell requires assistance 
from vectors. Vectors should not only be able to deliver the siRNA to the cytosol but also protect it from 
host nucleases. Recently, due to the vast interest in the siRNA therapeutic potential, a strong interest in 
the development of the non-toxic non-viral polymer-based vectors to improve the transfection efficiency 
was generated. Juanes et al.243 very recently explored the potential of amphiphilic polyhydrazones and 
the degree of polymerization for the intracellular delivery of siRNA. They also demonstrated that this
system could also be adopted for the complexation of mRNA.  
PEI, which played a crucial role in the plasmid DNA delivery, is not considered very efficient for 
siRNA delivery. The lower efficiency of PEI to transfect siRNA is because of the shorter length of 
siRNA as compared with the DNA molecules. The electrostatic force of attraction between the 
negatively charged siRNA and PEI is also not sufficient to hold the complex together, which dissociates 
at the anionic cell surface244. Another major concern with the use of PEI is its toxicity which severely 
limited its use in nucleic acid delivery245. However, recently due to the availability of the linear and 
branched derivatives of PEI in a wide range of molecular weight, interest in its delivery potential has 
been reestablished. Such derivatives are the less toxic variation of PEI with better protection for siRNA 
from the nucleases. The toxicity associated with PEI has been controlled by incorporating low molecular 
weight PEI into other polymeric constructs246.Chemical modification of the PEI also helps to introduce 
the functionalities like targeted delivery, higher resistance against the nucleases, better endosomal 
escape, prolonged systemic circulation, and external and internal stimuli-responsive release of 
siRNA13,247–249. The most feasible approach to mitigating the PEI toxicity is through the introduction of 
the hydrophobic characters. This approach, however, is associated with the reduction in the overall 
positive charges on the PEI, which could affect the polyplexes formation with siRNA. The optimum 
balance between the hydrophobic characters and overall positive charges is essential for the success of 
PEI in siRNA delivery. The addition of the alkylcarboxyl groups to the branched PEI is found to impart 
the hydrophobicity, and carboxylation up to 20% was found to be associated with the better endosomal 
escape250. An increased in the length of the alkyl chain, which is used to enhance the hydrophobic 
character, has also been associated with the improved stability of the siRNA complex and reduced 










Low molecular weight PEI, along with the low toxicity, also has low transfection efficiency. This 
issue was overcome by the introduction of disulfide bonds in the cross-linked PEI253–255. The optimized 
equilibrium between branch density and cleavable disulfide bond within PEI is found to be the crucial 
factor in achieving better siRNA delivery256. Kim et al.257 combined low toxicity and better transfection 
efficiency by conjugating the hydrophobic lipid anchor, cholesterol chloroformate to the cationic head of 
low molecular weight branched PEI257. This complex was used to transfect the siRNA designed to 
inhibit the vascular endothelial growth factor in human prostate adenocarcinomas257. For targeted 
delivery of siRNA to inhibit dihydrofolate reductase enzyme, Biswal et al.258 developed folate-
conjugated PEI. The complex was used to inhibit the folate reductase in human epidermal carcinoma258. 
Similarly, Yamaoka et al.259 conjugated pullulan with PEI for liver targeting .siRNA was complexed 
with pullulan-containing PEI. Pullulan has a very high affinity towards the asialoglycoprotein receptor, 
highly expressed on the liver cells, ensuring the targeted delivery of siRNA. Similarly, galactose has a 
high affinity towards the asialoglycoprotein receptors, which was also used for the targeted delivery of 
siRNA molecules260,261. PEI derivatives were also studied for the stimuli-responsive release of siRNA. 
For example, Lee et al. 262 conjugated PEI with embedded magnetite nanocrystals to develop stimuli-
responsive release of siRNA.  
PLGA is another polymer that is widely used for siRNA delivery. It is a copolymer composed of 
glycolic acid and lactic acid linked through an ester bond. The ester bond undergoes hydrolysis to form
the monomers back. The rate of hydrolysis depends upon and could vary with the ratio of monomers, 
total molecular weight, structure, and shape of the polymer. PLGAs having different proportions of 
monomers, molecular weight, structures, and shapes re developed commercially for various biomedical 
applications. Nanoparticles composed of PLGA have been widely screened for the delivery of drugs and 
gene-based products. PLGA has created huge interest as an alternative to viral-based delivery of 
siRNA263. They offer the advantage of small particle size, relatively non-toxic, and sustained release 
profile 264. In general, nucleic acids are loaded into PLGA-based nanoparticles by encapsulating it inside 
the core or by adsorption via electrostatic force of attraction between the modifie  positively charged 
surface of PLGA and negatively charged siRNA molecul s. PLGA nanoparticles have created huge 
interest in the delivery of therapeutics because of their high stability, higher endocytosis rate, targeting 
ability by conjugating them with the targeting ligands, and biodegradability. PLGA matrix can entrap 










the delivery formulation which facilitates safe and sustained, release profiles. For sustain release 
variation, degradation time of PLGA could be managed from days to years by varying the molecular 
weight and the ratio of its monomers256. The initial challenge in the loading of the negatively charged 
siRNA to the negatively charged PLGA nanoparticles is because there is no electrostatic interaction. 
Conjugation of the cationic moiety to the PLGA matrix could impart the stability and toxicity issues265. 
Such modification could also sometimes negatively affect the activity of siRNA. To overcome these 
flaws, Cun et al.266 used a double emulsion solvent evaporation method o incorporate the siRNA in 
PLGA nanoparticles. This research group successfully incorporated the siRNA inside the PLGA 
nanoparticles without affecting its stability and activity266. Although this approach is successful for 
loading siRNA in PLGA nanoparticles without the use of cationic conjugated, it has limited application 
because of the low loading and encapsulation efficincy266. The low loading is attributed to the repulsion 
force between the phosphate backbone of siRNA and the anionic acid groups in PLGA polymers. Using 
a similar method, Cun et al.267 also proposed various formulations of PLGA to load the siRNA 
molecules for therapeutic delivery. They optimized the formulations of PLGA by varying the siRNA 
load, PLGA concentration, ratio of monomers, water, and oil phase of the emulsion, and the amount of 
bovine serum albumin added to stabilize the emulsion. PLGA concentration was found to be critical in 
achieving the encapsulation efficiency of more than 70%. However, bovine serum albumin addition was 
found to enhance the encapsulation efficiency at lower PLGA concentration267. Despite of this 
outstanding character, with the lower electrostatic for e of attraction with siRNA, and lack of endosomal 
escape, PLGA nanoparticles could not be efficiently used for the siRNA delivery. One of the most 
versatile strategies to overcome this issue is the use of polycations into PLGA-based nanoparticles. This 
strategy successfully enhanced the loading capacity of PLGA nanoparticles. To date, cationic 
compounds like DOTAP, PEI, or polyamine are conjugated with the PLGA nanoparticles at the cost of 
toxicity and high siRNA retardation. It is, therefore, essential to make less use of the cationic conjugated 
and employ the optimal formulation methods to achieve higher siRNA encapsulation and better release. 
Wang et al.268 developed different nanoparticles for hepatitis B treatment with siRNA. The nanoparticles 
were composed of PLGA, methoxy poly (ethylene glycol)–poly (lactide) (mPEG–PLA), and chitosan 
and PEI for surface coating269.For the optimized transfection of siRNA, Andersen et al.270 developed a 
method to conjugate the PLGA nanoparticle surface with polyethyleneimine by using a cetyl derivative. 
The formulation was used to silence the TNFα in J774.1 cells. In this method, sub-micron size particles 










STAT3 in the dendritic cells is the crucial approach for cancer immunotherapy. Alshamsan et al.271 have 
successfully shown that STAT3 inhibition in B16 murine melanoma by siRNA polyplexes of PEI-linked 
PGLA promotes B16 cell death. Incorporation of the siRNA in the PEI-linked PGLA nanoparticles 
reduces the toxicity associated with PEI and also enhances the cellular uptake272. Different in vitro 
transfection efficiency study showed that the ability of PEI-linked PGLA nanoparticles to transfects 
depends on its ratio and the cell types273. Risnayanti et al. 274 recently proposed PLGA nanoparticles as a 
delivery vehicle for MDR1 and BCL2 siRNA to MDR ovari n cancer cells. In this formulation, poly-L-
lysine was used as a complexing agent for siRNA, which successfully inhibited the efflux of drugs from 
the ovarian cancer cells274. Patil et al.275 similarly developed PLGA nanoparticles for siRNA delivery, 
where they used PEI to enhance the electrostatic attraction between the siRNA molecules and PLGA 
matrix. The nanoparticles were prepared by using the double emulsion solvent evaporation method.  
Hasan et al.276 developed a new method called “particle replication in nonwetting templates” for the 
preparation of PLGA nanoparticles coated with the lipids to deliver siRNA to the prostate cancer cells. 
This method was found to have the high encapsulation efficiency of siRNA in PLGA nanoparticles. 
Wang et al.277 also developed PLGA‒PEG cationic lipid nanoparticles by using the commonly employed 
double emulsion method. These nanoparticles have shown the very high encapsulation efficiency of 
around 90%, which effectively inhibits the target gne.  
Chitosan, which is a linear polysaccharide made up of β-(1→4)-linked D-glucosamine (deacetylated 
unit) and N-acetyl-D-glucosamine (acetylated unit), has gained immense i terest in the pharmaceutical 
industry. The characters like natural origin, abundance, non-immunogenicity, biocompatibility, and 
biodegradability have contributed immensely to its popularity for biological applications. It also 
possesses positive charges, which help to form the complex with the negatively charged siRNA. This 
character of chitosan makes it a useful non-viral vehicle for the siRNA delivery. D-Glucosamine residue, 
which has a pKa value of about 6.2–7.0, gives weak basic character to the chitosan. At the pH below its 
pKa value, protonation of the primary amines imparted cationic character to it. Such positively charge 
polymer forms polyplexes with DNA and siRNA, which pose a negatively charged phosphate backbone. 
Chitosan-mediated delivery of DNA is widely studied; however, its application for siRNA delivery is 
getting momentum in recent times278. Since the last decade, various formulations of chitosan are under 
the development for the siRNA delivery. For example, chitosan aspartate, chitosan glutamate, chitosan 










fluorescent protein-expressing HeLa cells279. Chitosan water solubility was found to be increased when a 
water-soluble vitamin called thiamine pyrophosphate conjugated with the amine group of chitosan 
through its phosphate group. Also, the other amine groups of thiamine pyrophosphate, particularly the 
thaizolium moiety, remain protonated at physiological pH, allowing electrostatic binding with the 
negatively charged siRNA molecules. This enhanced attraction with siRNA and water solubility helps to 
increase transfection efficiency280. In another approach to introduce the secondary and tertiary amines, 
imidazole acetic acid was conjugated to the chitosan. This modification substantially helped to enhance 
the water solubility and endosomal escape of siRNA281. Interpolyelectrolyte siRNA/chitosan complexes 
developed by Howard et al.282 successfully overcame the issue of lower uptake and higher degradation 
of siRNA. A significant decrease in the enhanced green fluorescence protein-expressing epithelial cells 
in the bronchiole of mice via daily nasal administration of interpolyelectrolyte siRNA/chitosan 
complexes was observed282. As discussed earlier, calcium phosphate is an effici nt siRNA delivery 
system but suffers due to the inconsistent particle siz  formation and transfection efficiencies. To 
overcome the issue, Choi et al.283 developed the CaP nanocarrier system by adding cationic glutamine-
conjugated oligochitosan, which significantly enhanced the transfection efficiency. For pulmonary gene 
therapy, Ni et al.284 developed a pH-sensitive system composed of guanidinylated O-carboxymethyl 
chitosan and N-2-hydroxypropyltimehyl ammonium chloride chitosan for the successful delivery of 
siRNA to the lungs. The siRNA against the survivin delivered using this system, was found to inhibit 
cell growth by 30% and induced cell apoptosis by around 20%284. Sun et al.285 for efficient siRNA 
delivery developed poly(ethylene glycol)-modified chitosan carrier system. Improvement in the stability 
of siRNA, and better transfection efficiency of siRNA-loaded in poly(ethylene glycol)-modified 
chitosan nanoparticles in cancer cell line was observed285.  
As discussed before, synthetic cationic polypeptides like PLL and PLA have also been widely 
studied for their gene delivery capabilities. However, these polypeptides are cytotoxic when used alone 
due to the very high cationic charges on them286. Several attempts were made to resolve this issue by 
combining them with hyaluronic acid and chitosan287,288. Plianwong et al.289 reported an efficient and 
easy-to-prepare method to combine chitosan with PLA to deliver siRNA to the cancer cell (HeLa cells 
expressing enhanced green fluorescent protein). Low solubility in the physiological condition is another 
severe issue which has restricted widespread use of chitosan in the siRNA delivery. Hydroxybutyl 
chitosan, a derivative, soluble under the neutral condition, was used by Wan et al.290 to target the tissue 










Hydroxybutyl chitosan, in the future, has the potential to deliver the siRNA to target the cancer cells290. 
Arami et al.291 reported the magnetic nanoparticles composed of polyethyleneglycol‒lactate polymer, 
chitosan, and polyethyleneimine. The biocompatible nanoparticle was successfully used to deliver the 
siRNA to human breast cancer MCF-7 and leukemia K562 cells291. Shen at al.292 reported a polymer-
coated nanoparticle fabrication method for the siRNA delivery. The natural polyphenol (−)-
epigallocatechin-3-O-gallate, which is a major compound found in green ta, was used to form the 
siRNA nanoparticles292. The polyphenol (−)-epigallocatechin-3-O-gallate could form strong electrostatic 
bonds with negatively charged compounds like DNA, RNA and proteins via hydrogen bonds293. The 
polyphenol (−)-epigallocatechin-3-O-gallate-siRNA complex once formed, was coated with the low-
molecular-weight cationic polymer to develop the shll.294 Shen et al.294 also conjugated the polyphenols 
like phenol, catechol and pyrogallol with low molecular weight polymers to efficiently deliver the 
siRNA molecules to the cytosol. 
Polymer-mediated siRNA delivery to the cancer cells ha  several benefits, for example, it offers 
chemical modifications to make soluble derivatives, ligand conjugation for targeted delivery, 
biocompatibility, conjugation with inorganic materials, which can address various barriers related with
efficient siRNA delivery. The integration of multiple functionalities into polymeric siRNA delivery 
systems could have intense influences on biomedical research and the ability to transform the spectrum 
of the therapeutic field in curing cancer.  
6. Challenges, prospects and future plans in the delivery of siRNA  
6.1.Challenges  
In the coming time, siRNA holds the massive potential to be used as a therapeutic tool for genetic 
disorders. It provides a high degree of gene selectivity, which is difficult to achieve with the current 
treatment options. Thus, with the RNA-based therapeutics, the targets which were previously 
inaccessible can now be targeted selectively. For example, protein-coding and non-coding mRNAs and 
premRNAs, which were initially thought to be undruggable, can now be targeted with the siRNAs.  
Several approaches are under development for the siRNA delivery to cells, and few of them are 
under clinical investigation295. As the siRNAs carry the negative charge, they are hindered from entering 









is through the endocytosis process. To be effective, siRNAs must exit out of the endosomes; otherwise, 
it could leave the cells via exocytosis process or may degrade by ribonuclease enzymes. Due to the off-
site targeting, siRNA must be administered in the low dose, which prevents its optimum use. One of the 
most critical non-intended side effects is the innate immune system activation because of the immune 
motif in the siRNA sequence. Immune system activation motifs of siRNA could be identified by Toll-
like receptors triggering the immune response along with the production of interferons (α or β) and 
inflammatory cytokines296. 
Another major hurdle is the displacement of the natural siRNA from RISC meant for the normal 
physiological functions with the externally administered siRNA. In such cases, because of the partial 
binding of the siRNA, mRNA cleavage may not occur, but the cell could not carry out the normal 
cellular function297. Other factors that affect the effectiveness of the siRNA treatment include glomerular 
filtration, degradation by serum ribonucleases, endothelial barrier, and attack by immune cells297.   
6.2.Prospects  
The crucial aim of the research is the delivery of siRNA to the cancer cells after systemic administration. 
Leaky underdeveloped vasculature of growing tumors helps to uptake more nanoparticles inside the 
tumor via EPR. Still, only around 15% of the administered dose can accumulate in the tumor. Most of 
the lost treatment is linked to the nonspecific reticular endothelial system. For the uncharged compounds 
of molecular weight, less than 5000 Da is the uphill task. There are around 25 charged phosphodiester 
linkages forming the backbone of siRNA, which hinders the cellular uptake. On the other hand, nuclease 
enzymes of the blood cause the rapid degradation of siRNA, which further limits its bioavailability. 
Active transport via encapsulated ligand targeted nanocarriers offers the solution to this issue. 
PEGylated ligand targeted liposomal, or micelles are aimed to avoid the nonspecific reticular endothelial 
system clearance. These targeted nanocarriers exhibit better cellular uptake than the untargeted and, t 
the same time, protect the siRNA from the nucleases. Although siRNA has one specific mRNA target, 
reports of unintended silencing of the other genes having partial complementary regions causing severe 
side effects are available. Sometimes siRNA could also trigger the innate immune system to release pro-
inflammatory cytokines. A variety of chemical modifications has been applied to the siRNA, which have 
tremendously improved the stability of siRNA in the blood and reduce off-site deposition. The chemical 










modification of siRNA is the fluorination and methylation at the 2′-position298. Both these modifications 
are found to be well tolerated throughout sense and antisense strands. Primarily these modifications are 
aimed at enhancing the half-life of siRNA in plasma by protecting it from the nucleases. At present, we 
do not need to enhance the potency of the siRNA through chemical modifications. Preserving the 
existing potency is sufficient for the therapeutic purpose. However, when 2′-O-Me and 2′F-RNA 
modification was done in the same siRNA, 500 fold increase in the potency was observed when 
compared with the unmodified siRNA299. A report of enhanced degradation of mRNA is available when 
enoxacin is linked with the siRNA300. In addition to this, immune activation is another s vere issue 
related to siRNAs. Nonspecific immune response to the therapeutic siRNA may initiate the unwanted 
side effects. This issue could be resolved by downregulating the immunogenic characters of siRNA. 
Immune response towards the siRNA is a complex phenom on, the details of which are available 
elsewhere. In short, siRNAs are identified by the toll-like receptors, protein kinase, and helicases, which 
lead to the induced secretion of the pro-inflammatory cytokines. Few nucleotide sequences have been 
linked to the immune activation; for example, 5′-GUCCUUCAA-3′ is the immune stimulatory sequence. 
In fact, the RNA sequence rich in U nucleotide is more easily identified by the immune system via 
TLR7 receptors301. Immunogenic stimulation could be substantially reduced by chemical modifications; 
for example, siRNA modified with 2′F-RNA, 2′-O-Me, and DNA residues have shown to have no 
effects on cytokines76.  
Chemical modification of siRNA is a rapidly evolving field. Although considerable progress has 
been made in imparting the stability to the siRNA via chemical modifications, still they are sequence-
dependent. With significant development in the lipid and polymer bases nanocarriers and simultaneous 
advancement in the chemical modification, the possibility of translation of siRNA from the lab to the 
clinics is very high.  
7. Future plans  
We have achieved tremendous success in siRNA studie; however, to make it a successful therapeutic 
agent, improvement in safety, delivery, pharmacokinetics, and pharmacodynamics is required. The 
future success of siRNA will depend on the successful development of the nanocarrier with better 
loading, transfusion, and safety profile. The following section has discussed some of the immediate 










7.1.Enhanced endosomal escape 
siRNA inside the endosomes are the same as that of the outside of the cell. They have no therapeutic 
value unless they break the endosome and enter inside the cytosol. Chances of degradation at pH 4.5 of 
the lysosome are high if they do not escape from the endosome. Overall, endosomal escape is the major 
hurdle in the therapeutic application of siRNA. The present situation demands better external and 
internal stimulus-responsive polymers, which could release the drugs on exposure. Wei et al. 302 have 
developed an ultrasound-responsive polymersome based on PEO-b-poly(DEA-stat-MEMA) block 
copolymer to evaluate its intracellular anticancer drug delivery pathway and in-vivo systematic 
antitumor effect. This polymersome showed a favourable endosomal escape ability302. Puri et al.303 
recently studied sulfonated PEIs covalently linked to pyropheophorbide-α for photoactivation and 
modified amines (sulfo-pyro-PEI) for controlled endosomal escape. The results confirmed the on-
demand release of the siRNA on photostimulation. Multivalent peptide-functionalized bioreducible 
polymers were developed for enhancing endosomal escp . It has been noted that the optimum number 
of hydrophobic side chains is essential for the micelle’s assembly and cellular uptake, but an excess of it 
could lead to the less endosomal escape. Hence, in the future proper structural optimization of the 
polymers and construction of the nanoparticles are essentials to overcome the issue of the endosomal 
escape.  
7.2.Conjugation with proteins and antibodies 
Endosomal escape is an important event for the siRNA activity. The potency of the siRNA could be 
enhanced by increasing its serum half-life by conjugating with antibodies and proteins. One of them is 
the IgE (antibody), which is synthesized by the plasm  cells. IgE, once synthesizes, remains in the blood 
and tissues for weeks. IgE-siRNA complex is hypothesized to have a similar self-life in the blood304. 
However, the potency of siRNA under investigation was found to be lower than the unconjugated form. 
Another option for the conjugation could be albumin, which could not only assist the delivery to the 
cancer cells but also enhance the pharmacokinetic properties of the siRNA. Lower potency of the IgE-
siRNA complex does not ensure that the future work could have a similar impact. We have to keep 
investigating the other options until we could considerably increase the efficiency of the siRNA along 
with pharmacokinetic characters305. 










One of the hurdles of cancer therapy is the off-site targeting. siRNA engulfed inside the nanoparticles 
are not only protected from the nucleases and rapid clearance from the body but, when targeting ligands 
linked to such nanoparticles, the targeted release of iRNA is possible. When siRNA is entrapped inside 
the nanoparticle, the particle of less than 150 nm can easily reach the hepatocytes, but the similar 
fenestrations are not available in the other tissue, thereby restricting the entry. Several ligands targeted 
nanocarriers like galactose-linked liposomes were proven to be useful in enhancing the drug activity at 
the liver site. PEG conjugation is another method to avoid macrophage identification. Tumor targeting 
based only on PEGylation and passive diffusion through EPR is not always suitable for different types 
of cancer. Therefore, to reduce the off-site accumulation and to deliver siRNA inside the cancer cells, 
facilitated or active diffusion is the better choice. Ligand-conjugated endocytosis mediating delivery of 
the siRNA to the target cells could eliminate the possibility of the side effects and, at the same time, 
increase the efficiency of the siRNA. In the future, facilitated and active transportation, external stimuli 
mediation (e.g., magnetic field, ultrasonic waves, laser lights, sound, and light, etc.), and on-demand 
release of the siRNA needs to be explored further. Fo  such approaches to be successful, smart stimuli 
responding polymers are required.  
7.4.Multifunctional approach 
Several hurdles need to be overcome to achieve the maximum potential of the therapeutic siRNA. The 
hurdles are endosomal escape, lower cellular uptake, r pid excretion, degradation by nucleases, and 
immune stimulation306. Combining all the solutions in one delivery system could lead to the 
development of the ideal carrier, which, however, is a difficult task. A multifunctional system that could 
connect most of the characters of the ideal delivery system could potentially replace the existing 
systems. The inclusion of the endosomal escape motifs in a multifunctional platform without altering the 
cellular uptake and potency of targeting ligand could enhance the overall performance of the system307. 
The addition of the targeting ligand could reduce th  non-specific accumulation and, at the same time, 
could enhance the site-specific delivery. Chemical modification at the 2′ positon of RNA could protect 
the RNA molecules from nuclease degradation, and fusing lipids could enhance the cellular uptake. 
Combining all the motifs to get in one single devic would increase the complexity of the delivery 
system. Hence, it is indispensable to study the overall physiochemical aspects of each component, how 
they complement each other’s activity and, at the same time, perform their function independently308. 










As discussed earlier, one of the biggest challenges in the therapeutic translation of the siRNA is the
successful delivery to the cancer cells. This required the appropriate size of the nanoparticles conjugated 
with the ligands. Receptors for the targeting ligands are generally expressed on diseased cells. Such 
receptors assist in the endocytosis of the nanoparticles to which this ligand is linked. Several surface 
protein expression is enhanced in the disease conditi , and the ligands for such proteins are identified. 
The ligands could be the antibodies, aptamers, cell-penetrating peptides, etc. Other than targeting the 
different types of cells, ligands for the endothelial cells of the different organs could be a useful too to 
target the cancer of various organs. Identification of the ligand for the leucocyte, which in general is 
difficult to target, would be very useful in case of blood cancer and certain viral infections. In thefuture, 
transfection to a subset of leucocyte will be the challenge to meet. Very recently, CpG 
oligodeoxynucleotides, which binds to the TLR9 to initiate the innate immune response towards the 
foreign invention, was linked to the siRNA to target the B cells309. Similarly, an antibody against CD7 
protein was used to target the siRNA to the T cells310. Similar to leucocytes, it is very difficult to deliver 
the siRNA using nanocarrier to the neurons. Identification of ligands for the neurons could be beneficial 
for the treatment of brain cancer, Alzheimer's, Parkinsonism, and infections like encephalitis. Rungta et 
al. 311 have developed the siRNA –lipid nanoparticle system  to deliver siRNA to the neurons. Recently, 
polyelectrolyte‒gold nano assemblies were successfully used by Chaudhary et al.312 to deliver the 
siRNA to the neuronal cells. Solanki et al. 313 in 2013 have developed a delivery platform known as 
nanotopography-mediated reverse uptake to deliver siRNA to the neural stem cells. A major 
breakthrough was achieved in crossing the BBB when Rabies virus glycoprotein was used as a targeting 
ligand to deliver the siRNA to the brain314. Even after the progress in the siRNA biology and delivery 
system, we have to keep looking for new targets for leukocytes and other cancers. The use and 
expansion of the protein database, and peptide and aptamer libraries could be useful for the siRNA 
delivery in the future.  
7.6.Reducing toxicity of lipid and polymer-carriers 
Lipid carriers offer several advantages to carry the drugs and gene products like siRNA. The distinct 
advantages include protection from nuclease-based degra ation, site-specific targeting using targeting 
ligands, lower side effects, and better half-life o the drugs315. Liposomes prepared from lipids also have 
their disadvantages, which include a) large scaleup problems, b) low drug/siRNA entrapment efficiency, 










water-soluble drugs in the blood, and f) toxicity of the lipid components. Toxicity could occur because 
of toxic lipids or its metabolites, particle size large enough to block the small blood capillaries, 
interaction with the blood components, etc. Toxicity due to the lipids-based carriers is mostly because of 
the charges they carry. To minimize the side effect, it is necessary to select the lipids favoring the small 
particle size and total compositions, which support fewer overall charges on the surface. For example, 
the most commonly used lipid-based carriers are cationic liposomes, which can interact with several 
proteins, lipoproteins, and collagen leading to the formation of the aggregates or premature release of 
the drugs leading to the systematic toxicity316. Cationic lipids have proven to have hepatic toxicity; they 
inhibit the protein kinase c activity and could induce lung inflammations317. Cationic liposomes were 
also found to have a toxic effect on macrophages on h rt term exposure318. Conjugating the lipid carrier 
to the targeting ligand could help to reduce the side effects of the lipids. In the end, to overcome th  
issue of nanoparticle toxicity, it is advisable to access the key characters which contribute to the toxici y 
adequately, which include: a) proper physiochemical characterization, b) surface property 
characterization, c) proper assessment of in vitro toxicity studies, d) reactive oxygen species assay, e) 
toxicity studies in proper animal models, and f) genotoxicity studies. In the future, masking of the 
nanoparticle surface with various biocompatible and hy rophilic polymers would be the focus of the 
research to reduce the adverse effects. Agents like PEG, polyethylene oxide, polyoxamer, poloxamine, 
and polysorbate 80 were already under investigation for their role in offering the biocompatibility to the 
lipid nanocarriers319. Nowadays, the need for a more efficient surface masking agent is very high, and 
there could not be better agents than the natural polymers. Going forward, the future of lipid-based 
carriers in siRNA delivery to the cancer cells is bright.  
8. Conclusions 
Once inside the cell, siRNAs form the RISC and subsequently destruct the mRNA. However, due to the 
polyanionic charges, siRNAs are unable to cross the lipid membrane, making the suitable delivery 
vehicle an urgent requirement for siRNA-based therapi s. Cationic lipid base nanoparticles containing 
ionizable amino lipids are the promising vehicle for the negatively charged nucleic acids. Interaction of 
amino lipids with the endosomal membrane allows the better endosomal escape and bioavailability. 
Despite being the favourable candidate for drug delivery, serious side effects have restricted their use. 
Along with the development of novel delivery vehicles, the development of the new lipids with no side 
effects is inevitable. Scientists are paying more attention to the hard-to-transfect leucocytes by 










So far, many different types of cationic and polymeric nanocarrier delivery systems are developed. 
In this review, we have discussed the popular siRNA delivery systems and their potential in cancer 
treatment. But we still have a lot of challenges to deal with before they can become the trusted delivery 
systems. The journey of cationic nanocarriers from untargeted to target to LPD and LCP nanocarriers 
with distinct advantages of better exosomal escape and cellular uptakes is phenomenal. The literature 
studies revealed that the PEGylation is crucial as it helps the nanoparticle to hide from the macrophages 
and enhances the blood circulation time. Modification of the siRNA is also critical to protect the siRNA 
from the nuclease-based degradation. Despite the creation of several nanocarriers with different 
functionalities, the final availability of siRNA for mRNA destruction is very less. This indicates that 
there is a vast scope in enhancing the ability of the nanocarriers. Strategies for the endosomal escap, 
cell and tissue targeting, and development of the novel biomaterials are crucial for the translation of 
siRNA from the lab to the patients on the bed.  
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Table 1 Chemotherapy-based sensitization using siRNA. 
siRNA Target gene Target protein Target drug  Cancer Observation  Ref. 
Anti-MDR1 
silencing RNA 
ABCB1  P-gp 1 also known as MDR1 DOX or MTX 
 
Cancer known to 
overexpress the MDR1 
gene to develop drug 
resistance  
siRNA downregulated MDR1 
mRNA expression by 50% in 
breast carcinoma and 
osteosarcoma cell lines. It 
inhibited tumor cell proliferation 
up to 90% (P<0.01), when 
co-administered with DOX or 
methotrexate, despite the known 
chemoresistance of the cell lines. 
siRNAs reduced the IC of 
DOX and methotrexate by more 








DEK nuclear protein Mitoxantrone or 
piroxicam 
carboplatin 
TCC in canine  This study confirmed that DEK 
mRNA knock-down in canine 
TCC cell lines could inhibit 
proliferation, decrease cell 









 The outcome suggests that DEK 
inhibition may support cell 
survival and represent a valid 
target for novel therapeutics or 
combination therapies with 






Survivin, also called 
baculoviral inhibitor of 
apoptosis repeat-containing 5 
or BIRC5 
Gemcitabine Human pancreatic 
cancer cell lines of 
Panc-1 and BxPC3 
It was observed that the 
suppression of survivin could 
enhance the chemosensitivity of 















Myeloid cell leukaemia-1 Etoposide  U-937 AML cells The results confirmed that 
MCL-1 and survivin have a 
crucial role in cell survival and 






coding for the 
M2 subunit of 
ribonucleotide 






Simultaneous action of RRM2 
silencing and gemcitabine 
resulted in suppressed 











and Capan2  and reduced metastasis. The 
RRM2 silencing induced 




TYMS  Thymidylate synthase DOX Human colon cancer 
RKO 
TS1058 siRNAs were found to be 
effective inhibitors of TS 
expression and could 







VEGF DOX  Hep3B cells VEGF gene silencing was found 
to enhance the chemosensitivity 




RBFOX3  RNA binding protein, FOX-1 
homolog  
 




and HepG2) and 
human immortalized 
hepatic cell line MIHA 
RBFOX3 gene silencing induced 
the cell apoptosis, inhibited 
migration and invasion mediated 
by 5-FU  
21 
siRNA against SRC  c-Src tyrosine kinase also 
known as proto-oncogene 
Gemcitabine PANC1, MIAPaCa2, 
BxPC3, and Capan2 










c-Src tyrosine-protein kinase Src  pancreatic 
adenocarcinoma cell 
lines 
chemoresistance and could be a 
possible target for therapeutic 
agents 




Human head and neck 
squamous carcinoma 
cell lines HSC2 
(JCRB0622) and SAS 
(JCRB0260)  
EGFR gene silencing in 
combination with cisplatin, 5
FU, and docetaxel increased 
chemosensitivity of all the drugs 




STMN1  Stathmin, also known 
as metablastin and oncoprotein 
18  
Taxanes Human osteosarcoma 
cell lines (Saos-2 and 
MG63) 
Stathmin downregulation along 
with Taxanes showed potent 





MDR1  MDR1 PTX Human colon cancer 
cell line HT-29 
MDR1 gene silencing 
significantly reduced the MDR1 
expression in human colon CSCs, 








called baculoviral inhibitor of 
apoptosis repeat-containing 5 
Chemosensitivity Androgen-independent 
prostate cancer cell 
lines PC-3, PC-3M, 
and DU145, and 
Silencing of survivin by RNAi 
inhibited cell proliferation and 









or BIRC5 androgen-dependent 
prostate cancer cell 
lines LNCaP and 
22RV1  
prostate cancer cells 
 
Bmi1 siRNA BMI1  Polycomb complex protein 
BMI-1  
Cisplatin Human endometrial 
cancer cell line 
HEC1A and Ishikawa 
cell lines 
Duel treatment with cisplatin and 
BMI1 silencing resulted in a 
synergistic anti-cancer effect, 
which was higher than that was 




NRP1  NRP-1 DOX Human osteosarcoma 
cell SaOS-2 
NRP-1 gene silencing 
significantly enhanced 











LS174T and LS180 
Girdin silencing enhances 
chemosensitivity of colorectal 













which codes for 




Ribonucleotide reductase DOX PANC-1, a pancreatic 
carcinoma cell 
line, HEK293A, a 
human embryonic 
kidney cell line 
SiRRM2 was found to 
significantly inhibit pancreatic 
tumor growth alone or in 





HIF1A  HIF-1α Gemicitabine MIA PaCa-2 cells  The HIF-1α silencing resulted in 




DNMT1 siRNA DNMT  DNA methyl transferase  Taxol Human brain cell line 
GOS-3 (grade II/III 
oligo-dendroglioma, 
DMSZ, Germany) and 
U87-MG (grade IV 
glioblastoma)  
siRNA mediated silencing 
followed by Taxol after 48 h or a 
combination of siRNA followed 
by TMZ after 24 h was found to 




NTRK1 TrkA PTX Human breast cancer 
cell line MCF-7 
Results indicate that TrkA 
signalling plays a vital role in 
breast cancer chemo-resistance 
and metastasis. TrkA is an 











TGFB1  TGF-β1  Temozolomide SKOV3 cells Results indicate that TGF-β1 
silencing inhibits cancer cell 
growth and enhances 









lines AsPC-1, PANC1, 
and BxPC3, and the 
normal pancreas cell 
line HPDE6c7 
Duel action of Plk-1 silencing 
and gemcitabine chemotherapy 
has synergistic anti-cancer 





NFE2L2 Nuclear factor erythroid 




cell lines 143B 
(CRL-8303) and 
MG63 (CRL-1543)  
Recombinant NRF2-siRNA was 
effective to sensitize both 143B 
and MG63 cells to DOX, 
cisplatin, and sorafenib, which 
was associated with significant 
downregulation of NRF2-targeted 
ATP-binding cassette (ABC) 
efflux transporters (ABCC3, 
ABCC4, and ABCG2) 
36 










called baculoviral inhibitor of 
apoptosis repeat-containing 




expression by RNAi attenuated 
the malignant phenotype of 
hepatocellular carcinoma cells. 
Cells also showed decreased 
proliferation, increased apoptosis, 
and caspase-3 activity, and 
increased chemosensitivity to 
cisplatin 
AQP-5 siRNA AQP5  AQP-5 DOX DOX Resistant breast 
cancer cell line MCF-7 
(MCF-7/ADR)  
Inhibition of AQP-5 expression 
may reverse the drug resistance 
and enhance the chemosensitivity 
of breast cancer cells 
38 




called baculoviral inhibitor of 
apoptosis repeat-containing 
5 or BIRC5 
Cisplatin Human pancreatic 
carcinoma cell line 
Panc-1  
The knock-down of the survivin 
gene expression in Panc-1 cells 
effectively induced apoptosis 
with the simultaneous increase in 






ABCB1 P-gp 1 also known as MDR1 DOX CF-7/ADR cell lines siRNA and DOX-loaded micelles 
were found to induce apoptosis 
















called baculoviral inhibitor of 
apoptosis repeat-containing 
5 or BIRC5 
PTX MDR lung cancer cell 
line (H460/cDDP)  
siRNA targeting survivin has the 
potential to enhance the 
sensitivity of drug-resistant lung 
cancer cells to paclitaxel 
41 









Urothelial carcinoma  
 
Thymidylate synthase was found 
to play an essential role in the 
prognosis of upper tract urothelial 
carcinoma, and siRNA may be a 
principal-agent for urothelial 
carcinoma treatment  
42  
 
Table 2 Recent application of LPD for gene therapy. 





Guanidinium-containing cationic lipid, i.e., 
N,N-distearyl-N-methyl-N-2-(N′-arginyl) 
aminoethyl ammonium chloride, DOPA, 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 
cholesterol, protamine sulfate (fraction X from 
salmon) and calf thymus DNA 
MDR 
transporter 
DOX and siRNA against 
MDR tumors 
Enhanced DOX uptake was 
noted when VEGF siRNA (in 
LPD-I nanoparticles) and 
c-Myc siRNA (LPD-II 
nanoparticles) combined in 
nanoparticles. LPD-I, which 












DOTAP and targeted with 
PEG conjugated with 
anisamide  
Non-glycerol-based cationic lipid which includes 
guanidinium and a lysine residue as the cationic 
headgroup (DSGLA); two liposome formulation 





EGFR siRNA  LPD‒PEG‒AA developed 
with DSGLA delivered 
siRNA to the H460 cells. 
Although the siRNA 
delivered by LPD‒PEG‒AA 
containing either DOTAP or 
DSGLA could silence EGFR 
expression, a synergistic cell 
killing was only observed 
with DSGLA. The 
formulation containing 









glycol) and calf thymus DNA 
HSD17B1 17β-HSD1-siRNA Significant suppression of 
tumor growth in 
17β-HSD1-siRNA/LPD 
-treated group when 
HSD17B1 gene expression 
was knocked down. The 













shRNA-luc/protamine complexes coated with 
cationic liposomes consisting of DOTAP and 
cholesterol. PEGylated lipid (DSPE-PEG5000) 




shRNA The transfection efficiency of 
LPD-shRNA was higher than 
naked shRNA. shRNA 
delivered by LPD inhibited 
brachyury expression, 
enhanced apoptosis and 
downregulated mesenchymal 
biomarker and suppressed 
cell proliferation 
126 
LPD nanoparticles of 
multi-epitope peptides 
developed from the rat 
HER2/neu (rHER2/neu) 
oncogene 
LPD NPs, including DOTAP/CHOL liposomes, 














Results demonstrate that 
rHER2/neu-peptides (p5 and 
p435) and 
their encapsulation can 
induce 
an antigen-specific immunity
. This study also presented 
the first attempt to evaluate 












encapsulated in LPD NPs 
Lipid-polycation-hyaluron
ic acid  
Polymer metformin, Hyaluronic acid (for 
condensation), cationic 
1,2-dioleoyl-3-trimethylammonium-propane 
chloride salt (DOTAP) for liposome. 





VEGF siRNA, metformin PolyMet successfully 
combined the intrinsic 
anti-cancer efficacy of 
metformin with the capacity 
to carry siRNA to enhance 
the therapeutic activity of 
anti-cancer gene therapy 
128 
Targeted LPD conjugated 
with anti-EGFR antibody 







and MCF-7  
siRNA The in-vivo accumulation of 
targeted LPD was higher than 
that of non-targeted LPD in 
MDA-MB-231 tumor 24 h 














Table 3 Passive and active micelles targeting. 
Passive targeting of the micelles Active targeting of the micelles Ref. 
Depends on the permeability of the rapidly forming vasculature. 
Pathological conditions like inflammation support permeation of 
micelles into the solid tumors 
Depends on the ligands linked to the micelles and the expression of 
the receptor proteins on the cancer cells. Accumulation is 
supported by pathological conditions like inflammation 
192 
Accumulation inside the tumor preferably depends on the EPR 
effect  
Accumulation inside the cells depends on the targetin  ligand, 
receptor protein interaction, abundance of the receptor protein and 
EPR 
193 
Passive targeting via micelles takes advantage of the poorly 
developed vasculature. Vasculature with large fenestrations 
formto keep in pace with higher demand of the nutrien s and 
oxygen, which leaves the endothelial cells poorly aligned with a 
large opening between them 
Tumor cells for survival express several proteins at a higher 
quantity than the normal cells. This feature allows selective 
accumulation of such micelles  
194  
No need to modify the surface of the micelle with the argeting 
agent. PEGylation is required to reduce rapid excretion and 
enhance stability 
Polymeric micelles can be functionalized for active argeting by 
chemically modifying their surface with targeting li ands that 
show a strong specificity for antigens or receptors over-expressed 
on cancer cells 
195 
Preferential binding to the cancer cell is not required. 
PEGylation helps it to accumulate in the tumor via enhancing 
Actively targeted polymeric micelles decrease side-eff cts of drugs 









EPF effect facilitate cellular uptake by receptor-mediated endocytosis 
Does not guarantee the safe delivery of the DNA or siRNA to the 
cancer cells 
Benefits the intracellular delivery of macromolecules ike DNA, 
siRNA, and proteins 
197  
NA  Commonly used targeting, such as ligands including a tibodies 
and their fragments, proteins, small molecules, peptid s, aptamers, 






Table 4  Stimuli responsive siRNA delivery system. 
pH-Sensitive Redox sensitive Enzyme-sensitive 
micelles 
Ultrasound  Magnetic field  Temperature-sensitive Light-sensitive 
micelles 
Drug delivery from micelles 
depends upon the pH the tumor  
Drug delivery from 
micelles depends upon the 
change in the redox 
potential of the tumor 
microenvironment 
Drug delivery from 
micelles depends 
upon altered 









depends upon the 
application of the 
external magnetic 
Drug delivery from 
micelles depends on the 
effects of the 
temperature on the 
heat-sensitive polymers  
Drug delivery 
from the micelles 
depends on the 
UV‒Visible or 








cancerous cells high-pressure 
wave of a 
frequency of 
20 kHz  
field  trigger drug 
release  
The pH of the tumor is 6.5 due 
to high lactic acid production, 
whereas the pH of the healthy 
tissues is around 7.4.200 The pH 
of the internal cellular 
organelles drops between 4 to 6, 
depending upon the 
organelles.201 
Cancer cells have higher 
redox potential (100–1000 
fold higher) as compared to 
the outside of the cells 
Polymers used to 
make these micelles 
has the groups 
which are 
recognized by the 
enzyme or by the 









the range of 
20–100 kHz 
can penetrate 










Fe3O4 or Fe2O3. 
These materials 




composed of the 
heat-responsive 
polymeric block, which 
upon exposure to the 
different temperatures, 
undergoes the phase 
change. Hydrophilic to 
hydrophobic changes 
are more common. 
 
 
In these micelles, 
light-sensitive 
groups are 
included inside the 
block polymers, in 








cis to trans 
conversion or vice 
versa 
These pH-gradients have been 
exploited successfully to design 
Higher intracellular redox 
potential is due to the high 
These micelles 
could hold drugs in 
Such micelles 
could hold the 
These micelles 
hold the drugs in 
These micelles hold the 
drugs at one phase of 
These micelles 








pH-sensitive polymeric micelles 
which can release their 
therapeutic payloads when they 
encounter a change in the pH of 
their microenvironment 
concentration of the 
glutathione tripeptide 
(γ-glutamyl-cysteinyl-glyci
ne). Polymeric micelles 
designed using the 
disulfide linkage, which 
could hold the drug at its 
core under normal redox 
potential,l but release it 
upon destabilization of 
disulphite bridge in higher 
redox potential.  
the absence of 
enzymes or 
enzymatic products. 
The most common 
enzymes exploited 





enzyme engaged in 
glycolysis, 
angiogenesis, fatty 
acid synthesis, and 
matrix 
metalloproteinase. 




release it when 
they are 
disturbed upon 




the absence of the 
externally applied 
magnetic field 





the polymeric block but 
release it upon phase 
change after exposure 






release it after 
conversion to its 
alternate form 
upon exposure to 
the light source  
Most commonly used 
pH-sensitive polymers202 are 




The basic principle of 
redox-responsive 
polymeric drug delivery 
systems is to utilize the 
differences in redox 
potentials between tumors 
Azobenzene linkage 
is established at the 
copolymer junction 
of an amphiphilic 
diblock copolymer. 







Jiang et al. 203 





The most commonly 
























hyaluronic acid, alginic acid, 
acrylamide, aminoethyl 
methacrylate, polylysine, 
polyhistidine, chitosan, etc. 
 
and normal tissues. It has 
been demonstrated that 
GSH/glutathione disulfide 
is the most abundant redox 
couple in animal cells. In 
the cytosol and nuclei, the 
concentration of GSH 
reaches 10, while outside 
the cell, the concentration 
drops to about 2–20 
mmol/L. The tumor has 
4-fold higher GSH 
concentrations than that of 
healthy tissue. Disulfide 
linkages have been applied 
broadly in 
reduction-responsive 
polymeric drug delivery 
systems187 
enzyme 
azoreductase, in the 
presence of 
coenzyme NADPH, 
results in the 
cleavage of the 
azo-based 
copolymer junction, 
which disrupts the 
micellar assembly 
delivery belong 











cobalt by the 










after heating at 
120 °C  

















Function Block polymer Targeted/non-targeted  Cancer type Ref. 
Micelles combined DOX and PTX 
delivery  
PLGA-PEG Yes: TAT peptide 
(cell-penetrating 
peptide ) 
Human carcinoma KB cell 
line 
206 
Polymeric micelles for siRNA 
(siRNAs against VEGF) delivery 
through the bloodstream to tumor 




H2BGFP-HeLa cells mice 
model  
207 
Micelles for anti-VEGF siRNA 
delivery  
MPEG/PCL diblock copolymer Yes: TAT peptide 
(cell penetrating 
peptide) 
S-180 sarcoma cells 218 











macrophages (THP-1) or 
human breast cancer cell 
lines (MDA-MB-231 and 
MDA-MB-468) 
222 
Multifunctional hybrid micelles 
with shell embedded magnetic 
nanoparticles for theranostic 
applications (magnetic oxide and 
Pluronic F127 and peptide-amphiphile(PA) pal-AAAAHHD Controlled drug 
release using 
magnetic field stimuli 











Polyurethane was synthesized from biodegradable PCL and LDI Yes: folic acid L929 and HeLa cells 224 
Multi-functional multiblock 
polyurethane micelles (PTX) 
PDO and PCL-bearing pH-responsive hydrazone bonds  pH-sensitive drug 
release  
3T3 mouse fibroblasts and 





Self-assembling PEG2000-peptide-PTX conjugate, which contains the 
MMP2-cleavable octapeptide between PEG and PTX 
Yes: TAT peptide 
(cell-penetrating 
peptide) 
NSCLC xenograft mouse 
model 
226 
Hybrid micelle for co-delivery of 
PD-L1 siRNA and paclitaxel  





Micelles for the combination 
therapy with siRNA (siMDR-1) 
and chemotherapeutics (DOX) 
 
4-Polyamidoamine conjugated with PEG-phospholipid A2780 ADR, MCF7 
ADR and MCF7 
MDR cancer cells: human 
ovarian carcinoma (A2780 
ADR) and breast cancer 
(MCF7 ADR) 
228 
Light and pH dual sensitive 
micelles for siRNA delivery  
Light and pH-sensitive triblock copolymer of PEG-b-PDMAEMA-b-PPy  Light and 
pH-sensitive micelles  









Micelles for the co-delivery of 
MTX and survivin siRNA 
Polyethlenimine and mPEG Yes: linolenic acid  HeLa cells  209 
Hybrid micelles for glypican-3 
siRNA  
PLGA‒PDPH (3-(2-pyridyldithio) propionyl hydrazide) No OV2944-HM-1 cells 





hybrid micelles to deliver survivine 
siRNA  
 
PEI and mPEG amphiphilic polymers (PEI‒LA and mPEG‒LA) Linolic acid linked 
amphiphilic polymers 
A549 cells 211 
Facile hydrophobization micelles 
for siRNA (Plk1 siRNA )delivery  
PEG-b-PLA micelles No DA-MB-231 cells 212 
Micelles for EZH2 siRNA delivery  
 
MPEG-PCL and DOTAP Micelles protected 
siRNA delivery  
U87 cells and GL261  213 
Duel function targeted micelles for 
programmed cell death ligand 1 
(PD-L1) small interfering RNA 
(siRNA) delivery and indoleamine 
Cholesterol conjugated cell-penetrating peptide lin TT1 
(Chol-HHHHHHH-AKRGARST) 
Yes: cell-penetrating 
peptide conjugated  
4T1 cells and 4T1 mouse 











Multi-functional polymer micelle 
for the sequential delivery of 
VEGF siRNA and paclitaxel 
 
 
Triblock copolymer of PCL‒PEG‒PHIS Yes: folate conjugated  MCF-7 cells and HUVEC 
cells and MCF-7 




micelles for targeted intracellular 
co-delivery of DOX and 
Bcl-2 siRNA 
 
PEGylated cationic triblock copolymer of PAH-b-PDMAPMA-b-PAH Yes: folate conjugated MCF-7 cells 216 
Micelles as nanocarriers for 
7-ethyl-10-hydroxycamptothecin, 
USPIO, and siRNA against VEGF 
PDMA-b-PCL No Human colon 
adenocarcinoma cell line 
LS174T and LS174T 
grafted mice model  
217s 
Micelles for co-delivery of 
P-gp siRNA and DOX 
 
Triblock polymers of PEG-b-(PCL-g-PEI)-b-PCL  Yes: folic acid 
conjugated  
MCF-7 and MCF-7/ADR 












Multifunctional polymeric micelles 
for the co-delivery of ZEB1 siRNA 
and DOX 
 
Copolymer: PEG–PLL–PLLeu  No H460 cells and 
subcutaneous H460 mice 
model 
220 
Multifunctional Polymeric Micelles 
P-gp siRNA and DOX  
β-Cyclodextrin-poly-ethyl-enimine No MCF-7 andMCF-7/ADR cel 40 
Multifunctional micellar 
nanocarriers for targeted 
co-delivery of MDR-1 siRNA and 
DOX 
 
 PEO-b-PCL Integrin αvβ3-specific 
ligand (RGD4C) for 
active cancer targeting 
and the 
cell-penetrating 
peptide TAT for 
membrane activity 
The P-gp overexpressing 
human melanoma cell line 
MDA-MB-435/LCC6MDR1 
and female athymic nude 













Figure 1 Steps in RISC formation and function. Reprinted with the permission from 









Figure 2 Schematic representation of the elaboration of the transferrin targeted 
pDNA- or siRNA-CDP nanoparticles (RONDEL). Reprinted with the permission 










Figure 3 The formation process of liposome/phosphate/calcium (LPC) nanoparticles. 
Reprinted with the permission from Ref. 131. Copyright © 2010 Taylor & Francis 
Group. 
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